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Abstract 
 
Organometallic complexes containing transition metals, such as Ru(II), Os(II), Ir(III), 
have been moderately and recently used in medicinal chemistry as anticancer, 
antimalarial, antimicrobial or diagnostic agents. Current trends have led researchers to 
explore and define new synthetic methods in the quest for the design of new drugs and 
reduce the inherit associated toxic side-effects by using metal based compounds. 
Ferrocene based derivatives have been subjected to study for their biological and 
medicinal applications. Examples include ferrocenophane polyphenol, ferrocenyl 
quinone methides, ferrocenyl-aminoquinoline-carboxamide and a ferrocene-substituted 
hydroxytamoxifen, which has been proved as a potential new breast cancer therapeutic.  
Ferroquine displays antimalarial activity and ferrocifen is a tamoxifen-ferrocene 
anticancer agent. During the course of our research, we have focused on synthesizing and 
studying the biological activity of novel organometallic compounds containing the 
corresponding ferrocene moiety. We aimed to make, at least, 3 different families of 
compounds, which were cannabinoid receptor (CB1/CB2 receptor agonists), histone 
deacetylase (HDAC) selective inhibitors and general kinase inhibitors.       
 
Firstly, a review covering the state-of-the-art in bioorganometallic chemistry will be pre-
sented. Secondly, we started with the synthesis of a small library of compounds contain-
ing the following groups:  ferrocenylamine, 4-oxo-1, 4-dihydropyridine and dihydroquin-
oline. We used aminoferrocene as a bioisostere of the adamantylamine group where pre-
vious studies of compounds containing the latter group had showed it to effectively inter-
act with the cannabinoid receptors, CB1 and CB2. Some of our compounds displayed good 
to excellent potency in the nM range against the CB1 and CB2 receptors.    
 
Thirdly, we embarked to synthesise HDAC inhibitors knowing their potential as anti-
cancer drugs and trying to obtain, wherever possible, enzyme isoform selectivity. One of 
the well-known HDAC inhibitors is suberoylanilide hydroxamic acid (SAHA). Vori-
nastat, as it is also known, has received Food and Drug Administration approval for treat-
ing patients with cutaneous T-cell lymphoma. The compound developed in our group by 
replacing ferrocene for the phenyl ring in SAHA, called JAHA, is another example of a 
highly potent HDAC inhibitor. Our research led to compounds where the hydroxamic 
viii 
 
acid moiety in JAHA has been replaced by a benzamide group. This transformation has 
produced a significant effect in delivering a potent HDAC3 selective HDAC inhibitor. 
This is supported by biological studies and a molecular modelling rationalisation. 
 
N ex t ,  a series of oxindole based analogues have been synthesized by the Knoevenagel 
condensation reaction of:  5-(pentafluorosulfanyl)-1,3-dihydro-indol-2-one and 6-(pen-
tafluorosulfanyl)-1,3-dihydro-indol-2-one compound with: ferrocenecarboxaldehyde and 
pyrrole-2-carboxaldehyde. The compounds thereby synthesised have been studied against 
a panel of kinases, and kinase inhibitory data will be discussed and presented.  
 
In a Future directions section, we will describe the synthesis of FAAH (fatty acid amide 
hydrolase) inhibitors based on an aminoferrocene backbone. 
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    Chapter 1 
Introduction 
 
1.1 Uses of iron complexes in medicinal chemistry 
Cisplatin is no doubt the best known and most used metal complex in 
chemotherapy.1 Many cisplatin analogues have since been developed and used for cancer 
chemotherapy, for example, carboplatin, oxaliplatin, heptaplatin, nedaplatin and 
lobaplatin, to address issues such as toxicity, resistance, selectivity and limited cancer 
scope of cisplatin.2  
 
Figure 1.1. Cisplatin and its analogues.  
 
These results have induced researchers to design other novel metal complexes for 
chemotherapy. Iron is also one of the essential transition metals that can be found in the 
body and is involved in many biological systems such as haemoglobin, transferrin and 
cytochromes.3-4 In many publications iron complexes have displayed potent anticancer 
activities.5-6 Usually iron has two common oxidation states in ferrous, Fe(II) and ferric 
forms, Fe(III). The first reported anticancer iron compounds were ferrocenium picrate 
and ferrocenium trichloroacetate salts.7-8  
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Ferrocene and its derivatives are popular iron complexes that researchers have 
synthesised and studied for their biological effects given its stability in aqueous and 
aerobic media and its electrochemical properties.9-10  
 
1.2 Background on ferrocene  
 
Ferrocene or dicyclopentadienyliron or bis(5 – cyclopentadienyl)iron is a 
compound containing iron (II) and two cyclopentadienyl rings. It was accidentally 
discovered by 2 groups; Peter L. Pauson and Thomas J. Kealy11 in 1951, when they 
attempted to make fulvalene, and by Samuel A. Miller when they had tried to prepare 
amines from saturated or unsaturated hydrocarbons and nitrogen, they reacted 
cyclopentadiene and N2 at 300 C, but they obtained the unexpected product.12-13 They 
obtained a yellow solid compound, however the chemical formula did not fit with C10H8 
but was formulated as FeC10H10.
14 The compound structure is contributed by resonance 
and intermediate forms (Figure 1.2). 
 
 
 
 
Figure 1.2. The compound structure proposed by Pauson and Kealy.  
 
Later, three chemists; Ernst Otto Fisher, Robert B. Woodward and Geoffrey 
Wilkinson15 were persuaded that the structure proposed by Pauson and Kealy was wrong 
and they contributed the new structures which have the same electronic configuration as 
krypton (Kr, noble gas) (Figure 1.3). Woodward16 suggested the name of ferrocene for 
[Fe(C5H5)2] and later applied to the chemicals in general form [M(C5H5)2] called 
metallocenes (or sandwich compounds). 
 
 
 
 
  
 
Figure 1.3. The compound structure proposed by Woodward and Wilkinson 1 
              and by Fischer 2.  
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 Ferrocene is a π-complex in which interactions between the d-orbitals of the Fe2+ 
metal centre with the π-orbitals of the two planar cyclopentadienyl ligands (C5H5-) form 
the metal-ligand bonds. Ferrocene is an air stable orange solid and it can be oxidized to 
the ferrocenium cation, [(C5H5)2Fe]
+. Ferrocene at room temperature crystallizes in a 
monoclinic form and shows the staggered conformation (D5d), while in the gas phase it 
has an eclipsed conformation (D5h).
17 The discovery of ferrocene was a starting point of 
organometallic chemistry18 and then has been merged with biochemistry to herald a new 
area of chemistry called bioorganometallic chemistry19-20 and the use of ferrocene in this 
area has increased rapidly.  
 Ferrocene and its derivatives have been used in many areas such as bio-analysis, 
bioconjugation, material sciences, organic synthesis (chiral catalysis), homogeneous 
catalysis (olefin polymerization), fuel additives, medicinal chemistry, and so on. In our 
research, we have focused on using ferrocene in medicinal chemistry. 
 
1.2.1 Chemistry of ferrocene  
 
 The cyclopentadienyl rings in ferrocene are aromatic and undergo many reactions 
similar to benzene. Ferrocene is more reactive than benzene, since it is more electron rich, 
in electrophilic substitutions. Some important reactions of ferrocene include Friedel-
Crafts acylations and lithiation reactions (Scheme 1.1).21  Friedel-Crafts reaction are a 
group of reactions ennabling the substitution of an aromatic ring developed by Charles 
Friedel and James Crafts in 1877.22 In the case of ferrocene acetylations or alkylations 
proceed by adding keto or alkyl groups to the cyclopentadienyl ring using an acetic 
anhydride/acetyl chloride or alkyl halide under Lewis acid catalysed conditions.23 Here, 
formally the electrophile replaces the hydrogen atom and a new carbon-carbon bond is 
formed (Scheme 1.1). 
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Scheme 1.1. Some reactions of ferrocene.   
 
1.3 Bioisosteres in medicinal chemistry 
 
 Bioisosteres are atoms or chemical groups with similar physical or chemical 
properties, which are usually used in drug design. The use of bioisosteres introduces 
structural changes. Bioisosteres are useful to address a number of aspects connected with 
the design and development of drug candidates, for example, improving potency, 
increasing selectivity, modifying some physical properties, reducing toxicity and so on. 
Bioisosteres can be classified in 2 different groups, which are classical and nonclassical 
bioisosteres.24-25 
 
1.3.1 Classical bioisosteres  
 
Classical bioisosteres show the results of an early evaluation of the concept and 
include structurally simple atoms or groups. Examples of classical bioisosteres and 
isosteres are shown below: 
 
1.3.1.1 monovalent atoms or groups. such as:  
D and H, F and H.  
NH2 and OH, RSH and ROH. 
F and CH3, Cl and OH, etc. 
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1.3.1.2 divalent atoms or groups. such as:  
C=C, C=N, C=O, C=S, –CH2–, –NH–, –O–, –S– 
 
1.3.1.3 trivalent atoms or groups. such as:  
–CH=, –N= 
 
1.3.1.4 tetrasubstituted atoms. such as: 
 R4C, R4Si, R4N
+ 
 
1.3.1.5 ring equivalents. such as: 
 
 
 
 
1.3.2 Non-classical bioisosteres  
 
 Non-classical bioisosteres are structurally distinct, normally containing different 
number of atoms and display different steric and electronic properties. Non-classical 
bioisosteres can be divided into 2 different groups, which are 1) cyclic and acyclic 
bioisosteres and 2) exchangeable group isosterism in which the properties of separate 
functional elements are imitated. Example of non-classical bioisosteres; include a 
tetrazole, which is a more lipophilic bioisostere of a carboxylic acid and indole is a 
bioisostere of a phenol (Scheme 1.2). 
 
 
 
 
 
 
Figure 1.4. Some non-classical bioisosteres.   
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1.4 Applications of ferrocene in medicinal chemistry  
 
Ferrocene has attracted special attention as it offers attractive properties such as 
neutrality, lipophilicity, good redox properties, chemical stability and low toxicity.26-27 A 
lot of ferrocenyl compounds display fascinating antifungal,28-29 antimalarial,30-31 DNA-
cleaving,32 cytotoxic33 and antitumour activity.34-35 The use of ferrocene in medicinal 
chemistry is a vigorous research area, some ferrocene derivatives are highly active in in 
vitro and in vivo assays. 
In 1978, the anticancer potential of ferrocenyl compounds bearing amine or amide 
groups against lymphocytic leukemia P-388 cell lines, was disclosed.36 Their concept was 
to design a ferrocene compound that can bind to a tumour cell surface nucleic acid 
bringing about an immune response. Polyamines, for example, putrescine, spermidine 
and spermine have been generally found in nature and interact strongly with nucleic 
acids.37 These compounds were tested along with a ferrocene derivative in mice, and 
showed that the presence of a ferrocenyl group could increase antitumour activity (Figure 
1.5).36 
 
 
Figure 1.5. The compound structures of putrescine, spermidine, spermine  
                  and ferrocenyl bearing amide group.  
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 A ferrocenyl group was linked to the acridine group of 3 (Figure 1.6) and the 
resulting compound 4 was compared with a benzylamine compound 5. In vitro studies 
showed the compound 4 was highly toxic to cancer cell line tested, but the benzylamine 
analogue 5 was inactive. From these results they concluded that combining the cytotoxic 
effects of a ferrocenyl group with the DNA intercalation ability of an acridine led to 
enhanced target binding and increased cytotoxicity.38 
 
  
 
 
 
 
 
Figure 1.6. Structures of an acridine 3, a ferrocenyl acridine 4  
                           and a benzylamine containing ferrocene 5.  
 
In 2005, ferrocenyl compounds were studied for their biological activity against 
topoisomerase IIα and β. Topoisomerases are enzymes that are involved with the winding 
and unwinding of DNA. In normal cells the activity of topoisomerase II is highly 
regulated but in cancer cells it is overexpressed. The results showed that 6 and 7 (Figure 
1.7) interacted with topoisomerase II and inhibited its activity thus causing cell death.39     
 
 
 
 
 
Figure 1.7. Azalactone ferrocene 6 and a thiourea ferrocene 7.  
 
A series of ferrocenyl compounds was tested in vitro against the human lung 
carcinoma cell line H1299. Most of them showed IC50 values lower than 10 µM.
40-41 
Especially, the -aminobutyric acid ethyl ester, 8 (Figure 1.8)42 had an IC50 value of 0.62 
µM, which is more active in vitro than cisplatin.43  
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Figure 1.8. An anticancer ferrocene derivative. 
 
 Azole compounds including adenine, imidazole and pyrazole are used as 
privileged structures in many drugs and have attracted many researchers (Figure 1.9). For 
example, a series of ferrocenylalkyl azoles were studied for tumour growth inhibition and 
toxicity in vivo. The results are comparable with cisplatin. The results showed compound 
9 was the best with up to 100% tumour growth inhibition.44  
  
 
 
 
 
 
 
 
 
 
Figure 1.9. Some examples of ferrocenylalkylazole compounds. 
 
They suggested that compound 9 was successful because; (1) the lipophilicity of the 
ferrocenyl group which enabled membrane permeability, (2) the hydrophilicity of the 
benzotriazolyl group enabled transport in aqueous media, (3) the ferrocenium form can 
be generated, (4) the azolyl group can form hydrogen bonds with the phosphate groups 
of DNA, (5) the planar heterocyclic ring in the molecule can intercalate between the 
planes of DNA nucleic bases, (6) the flexible, swinging, alkyl bridge can aid formation 
of ligand-receptor complexes.44 
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 Retinoids are a class of chemical compounds related to vitamin A and play an 
important role in vertebrate growth and development, embryonic development, immune 
response, supporting cell differentiation and reproduction.45 Some trans-retinoid acids are 
currently used for treatment of dermatological diseases and used as chemotherapeutic 
agents against various cancer cells. Their actions involve binding and activation of the 
retinoic acid receptors (RARs) or retinoid X receptors (RXRs).46 A novel retinoyl 
derivative of ferrocene, 15 (Figure 1.8) was synthesized and studied their antiproliferative 
activity toward a human lung cancer cell line (A549), human liver cancer cell line 
(BEL7404), and human tongue cancer cell line (Tca), although the results showed 
ferrocenyl analogues had higher antiproliferative activities when compared to the parent 
13-cis-retinoic acid (IC50 = 0.46 - 1 µM) , the IC50 values of novel compounds are being 
19-40 µM.47  
 
 
 
 
 
 
Figure 1.10. 13-cis-retinoic acid and retinoyl derivative of ferrocene. 
 
 Ferrocifens are the most widely studied of ferrocene derivatives for cancer 
therapeutics, which have promising results for breast cancer.48-49 Jaouen and co-workers 
have synthesized e.g. 16, 17 and 18 (Figure 1.11).  18 was differentiated by the length of 
the alkyl chain connected to the dimethyl amino group, n = 2-5, and 8.48-49 The 
antiproliferative effects of 18 were assessed on MCF-7 cells (hormone-dependent breast 
cancer cells), 18 being slightly more potent than hydroxytamoxifen at 0.1 µM 
concentration and higher at 1µM. While 17 was inactive on hormone-independent cells 
and 18 showed a remarkable low IC50 value. 
48-49 
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Figure 1.11. Structures of tamoxifen 16, hydroxytamoxifen 17  
                           and hydroxyferrocifens 18.  
 
A comparison of compounds 19 and 20 (Figure 1.12) differing by the linkage in 
the cyclopentadienyl rings, showed the conjugated compound 19 is more cytotoxic than 
the non-conjugated compound 20 with the antiproliferative effect on hormone-
independent PC-3 cells and MDA-MB-231 with IC50 value of 0.09 µM.
50-51 
 
 
 
 
 
 
 
 
Figure 1.12. Ferrocenophane compounds structurally related to tamoxifen.  
 
 The same group also synthesized and characterized a new family of 
ferrocenophanic suberamides (Figure 1.13) with potent antiproliferative activities against 
triple-negative MDA-MB-231 breast cancer cell lines and hormone dependent MCF-7 
breast cancer cells. The results showed redox activation could occur in the 
ferrocenophane. Hence, they can be converted into ferrocenium intermediates, which are 
able to show a strong antiproliferative activity of ferrocene and ferrocenophanic 
compounds.52   
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Figure 1.13. Ferrocenophanic suberamides. 
 
Replacement of a phenyl ring by a ferrocenyl moiety, on raloxifene (21, Figure 
1.14), maintained cytotoxic activity against ovarian, cervical, lung, colon and breast 
cancer cell lines. Among all the compounds, [3-ferrocenyl-6-methoxybenzo[b]thiophen-
2-yl][4-(piperazin-1-yl)methylphenyl]methanone (22, Figure 1.14) showed IC50 values in 
the low-micromolar range, lower than those of cisplatin.53  
 
This represents a general strategy in this body of work, whereby a phenyl or bulky 
alkyl group is replaced by a ferrocenyl group, thereby modifying the molecules’ physical 
properties without adversely affecting its biological activity as in the “bioisostere” (bio-
equivalent) replacement approach (Section 1.3)  
 
 
 
 
 
 
 
 
 
Figure 1.14. raloxifene 21 and “FeCp”- raloxifene 22 
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 Jaouen and co-workers attempted to improve the therapeutic activity of nilutamide 
(23, Figure 1.15) by replacing positions in the molecule by a ferrocenyl group (nilutamide 
is a non-steroidal anti-androgen therapeutic used in prostate cancer). The novel compound 
(24, Figure 1.15) showed cytotoxic activity against PC-3 hormone-independent prostate 
cancer cells with an IC50 value of 5.4 µM. The idea of attaching ferrocene to androgens 
and anti-androgens seems to be a promising way to create efficient drugs for hormone-
dependent prostate cancers.54   
 
 
 
 
 
 
Figure 1.15. Nilutamide 23 and a ferrocenyl-nilutamide analogue 24.  
 
Novel hydroxyl-substituted Schiff-bases were synthesized containing ferrocenyl 
moieties and were evaluated for their antioxidant and anticancer activities. The results 
showed dual antioxidant and anticancer activities for compound 25 (Figure 1.16), which 
contains both ferrocenyl and o-dihydroxyl groups. The ferrocenyl moiety has dual 
functions; increasing the lipophilicity and lowering the redox potentials of the o-
dihydroxyl groups.55  
 
 
Figure 1.16. Hydroxyl-substituted Schiff-bases containing ferrocenyl moieties.  
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 A series of novel iminosugar–ferrocene hybrids displayed potent inhibition of 
fucosidase (bovine kidney) and inactivation of MDA-MB-231 breast cancer cell 
proliferation at the low µM range. A number of compounds were prepared by varying the 
length of the linker connecting ferrocene to the iminosugar for establishing structure–
activity relationships (Figure 1.17).56 
 
 
 
 
 
Figure 1.17. Iminosugar–ferrocene hybrids. 
 
The antimalarial, chloroquine 29 has been used extensively since its original 
synthesis.57 Recently researchers have improved this by replacing the alkyl linker by a 
ferrocenyl group and called the resulting molecule “ferroquine” 30. Ferroquine is a novel 
antimalarial drug candidate and was designed by Christophe Biot.58 Malaria is caused by 
single cell protozoon parasites of the Plasmodium species, of which P. falciparum is the 
most dangerous. 30 proved to be the best antimalarial candidate (Figure 1.18).59 
 
 
 
 
 
 
 
Figure 1.18. Antimalarials chloroquine 29 and 30 ferroquine.  
 
Spencer and co-workers have designed ferrocene analogues and shown them to 
have anticancer activity and act as metallodrugs in many examples such as erlotinib and 
gefitinib. Some ferrocene analogues based on a 6,7-dimethoxy-N-phenylquinazolin-4-
amine template have been synthesized (compounds 31, 32 and 33) and tested for in vitro 
anticancer activities against epidermal growth receptor (EGFR) with IC50 value in the 
sub-µM range (Figure 1.19).60 
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Figure 1.19. Ferroence-based EGFR inhibitors. 
 
Suberoyl anilide hydroxamic acid (SAHA) is a compound that shows promise for 
the treatment of cancer and has been clinically approved against CTCL (cutaneous T-cell 
lymphoma). SAHA 34 has activity against HDACs (histone deacetylases) and is effective 
in cancer cell lines.61 Other work from Spencer and co-workers described N8-ferrocenyl-
N1-hydroxy-octanediamine (JAHA), an analogue of SAHA, containing a ferrocenyl 
group as a phenyl bioisostere. JAHA  analogues 35 displayed anticancer activity and 
inhibition of some classes of HDACs.62 “Click JAHAs” 36 also have been synthesized 
and displayed excellent HDAC inhibition, Figure 1.20.63  
 
 
Figure 1.20. SAHA 34, JAHA 35 and click JAHAs 36.  
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 Tucker’s group have studied functional supramolecular systems and ferrocene 
chemistry, and some of their work focused on designing the molecules containing 
ferrocene e.g. by using ferrocene to mimic the DNA structure (artificial nucleic acids) 
called ferrocene nucleic acids (FcNA), 37. The phosphate-sugar-phosphate fragment in 
an oligomer is replaced by ferrocene molecule, the eight units of ferrocene and sixteen 
thymine (T) nucleobases gave the molecule called (Fc-TT)8, 38 and they then studied their 
electrochemical behaviour.64 Later, in 2014 they reported nucleoside analogues 
containing ferrocene as a replacement of the five-membered sugar ring and in the cell 
lines studied they found these novel ferrocenyl nucleoside analogues display anticancer 
activity, e.g. 39.65  
 
 
 
Figure 1.21. FcNA 37, (Fc-TT)8 38 and nucleoside-Fc 39.  
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 Gasser and co-workers are also interested in the synthesis and study of the 
biological activity of organometallic compounds and recently reported the synthesis and 
biological study of sandwich and half-sandwich derivatives of platensimycin, a natural 
antibiotic. The results failed to show any antibacterial activity and they reasoned that this 
could be because of cell permeability problems of bioorganometallics.66 Gasser also 
synthesized ferrocenyl derivatives of praziquantel (Fc-PZQ) against schistosomiasis, 
where praziquantel (PZQ), 40 is a drug for treat some types of parasitic worm infections. 
The results in vitro showed that some compounds have the IC50 values in the µM range. 
Even the most active compound was not good enough to go through in vivo testing but 
this study will be open new mode in the search for novel drug candidates against 
schistosomiasis.67 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.22. Praziquantel (PZQ) 40, Fc-PZQ (type-A) and Fc-PZQ (type-B).  
 
 Other work from Gasser has shown the synthesis of light activated organometallic 
HDAC inhibitors, p-Fc-SAHA (41, Figure 1.22), that release a JAHA-type HDAC 
inhibitor,68 as shown in the cleavable linker. 
 
 
 
 
 
 
 
Figure 1.23. Light activatable organometallic HDAC inhibitor, p-Fc-SAHA.  
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Orvig and co-workers have synthesized and studied the anticancer activity of 
ferrocenyl-aminoquinoline-carboxamide conjugates, 42 and 43 (Figure 1.24), in vitro and 
these showed good activity against human breast cancer cells. The ferrocenyl derivatives 
were highly potent against colon and breast cancer cells but not very selective versus 
normal cell line.69 
 
 
 
 
 
 
 
Figure 1.24. ferrocenyl-aminoquinoline-carboxamide conjugates compounds.  
 
 Carbonic anhydrase (CA) inhibitors have uses in the treatment of glaucoma, 
seizure disorder and so on. CA is an enzyme that catalyzes the decomposition of carbonic 
acid into carbon dioxide and water and CA exists in several isoforms including CA II, IX 
and XII. Metallocene-based compounds have been synthesized and evaluated as carbonic 
anhydrase inhibitors (Figure 1.25) by Poulsen and colleagues. They used either ferrocene 
or ruthenocene in the molecules. In vitro studies found these compounds were moderate 
to good CA inhibitors, and compounds containing a metallocene fragment showed similar 
SAR to the phenyl rings but in CA II, IX and XII the metallocene compounds have better 
potency to CA inhibition compared to phenyl-compounds.70 
 
 
 
 
Figure 1.25. Some novel ruthenocene and ferrocene-based CA inhibitors. 
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 The synthesis and biological evaluation, in two murine cell lines (mouse 
embryonic fibroblasts, NIH-3T3 and pheochromocytoma of the rat adrenal medulla, PC-
12) and two human cell lines (adenocarcinomic human alveolar basal epithelial cells, A-
549 and hepatocellular carcinoma, Hep-G2) of gold complexes incorporating different 
ferrocenyl-amide phosphine ligands (Figure 1.26) was carried out. These were compared 
with silver analogues. The results showed the gold complexes to be more active than the 
silver derivatives.71 
 
 
 
 
 
 
 
Figure 1.26. Some gold complexes with ferrocenyl-amide phosphine ligands. 
 
A series of ferrocene-appended terpyridine copper(II) complexes combined with 
phenanthroline bases (Figure 1.27) was synthesized and their DNA binding, 
photoinduced DNA cleavage activity in visible light, and cytotoxicity in HeLa cells were 
studied. The results showed efficient DNA photocleavage activity in visible light at 
different wavelengths. These results are of importance toward developing the chemistry 
of bioorganometallic complexes as metal-based photoactivated anticancer agents 
showing DNA cleavage activity.72 
 
  
 
 
 
 
 
 
 
 
Figure 1.27. Some ferrocene-appended terpyridine copper(II) complexes 
                  with phenanthroline bases. 
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Ruthenocenyl-6-aminopenicillinic acid and ferrocenyl compounds have been 
synthesized and their antibacterial activity studied against CTX-M-β-lactamase. The 
researchers obtained the crystal structure of these organometallic complexes and protein 
residues. In this conclusion they found compound 53 to be an inhibitor of β-lactamase, 
and the potential use of this product as a novel scaffold for drug discovery against β-
lactamases, while compound 52 was inactive due to the steric clashes and electrostatic in 
the protein.73 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.28. Structures of 51 and hydrolyzed products 52 and 53. 
 
 Ferrocenyl paclitaxel and docetaxel analogues have been synthesized and their 
antiproliferative and cytotoxic effects studied. They used ferrocene as a bioisostere of a 
phenyl ring and the results showed the most active compound to be 54, which has  better 
antiproliferative activity than that of the parent (paclitaxel or taxol) compound with an 
IC50 of 0.11 versus 1.11 µM. (Figure 1.29).
74 
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Figure 1.29. Ferrocenyl paclitaxel analogue. 
 
 Two isomers of clotrimazole (55 and 56) have been synthesized by replacing the 
phenyl ring with ferrocene and their cell growth inhibitory activity on two types of human 
cancer cell lines was tested. It was found that the cytotoxicity of the ferrocene analogues 
showed almost twice increase activity against HT29 colorectal cancer cells, whilst the 
activity against MCF-7 breast cancer cell lines was close to the parent compound.75 
 
 
 
  
 
 
 
 
Figure 1.30. Ferrocene-clotrimazole compounds 55 and 56. 
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1.5 Other metal complexes in medicinal chemistry 
 
 As stated earlier, cisplatin is a widely used anticancer agent and this success has 
inspired researchers to develop other metal-based drugs and apply these to other 
applications in medicinal areas such as using the organometallic complexes in 
fluorescence cell imaging,76 contrast agents in MRI77 and so on. 
 
 Fluorescence cell imaging relates to the use of chemicals for monitoring organ, 
tissues, some diseases or even tracking systems inside the body, as in a selection of 
imaging agents 57, 58 and 59 based on a variety of metal atoms i.e. Rh, Re and Tc, 
respectively. 
 
  The bioconjugation of a rhodium (Rh) complex with biotin has used as a 
fluorescent stain in cell imaging, (Figure 1.31) also known as called “biotinylation”. 
Biotin is a vitamin B7, it is a coenzyme for carboxylate enzymes related with the synthesis 
of isoleucine, valine, fatty acids and metabolic pathway of the generation of glucose 
(gluconeogenesis). The results showed 57 had luminescence properties inside cells.78  
 
 
 
Figure 1.31. Rh complex imaging agent. 
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The design of Re(CO)3-based complexes has been developed over the last 15 
years.79 Many luminescent rhenium complexes which target different organs have been 
studied and published, (Figure 1.32) e.g. 58.76-80 
 
 
 
 
 
 
 
 
 
 
Figure 1.32. Re complex imaging agent. 
 
Technetium (Tc) complexes have been synthesized and used as cell imaging 
agents.81 Tc is the most widely used in diagnostic medicine, a number of Tc-based 
radiopharmaceuticals have been developed and approved by the FDA.82 Figure 1.33 
shows an example of a Tc cell imaging agent 59.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.33. Tc complex imaging agent. 
 
 
 
 
23 
 
 Nuclear magnetic resonance (NMR) is used for determining compound structure. 
The related magnetic resonance imaging (MRI) uses a similar principle but with a larger 
magnetic field size. It is used for medical diagnosis by detecting the difference between 
water molecules according to their environment, either in fluids or soft tissue in the body. 
Patients will take the paramagnetic metal complex before running the MRI, in this case 
the image will be enhanced due to the complex acting as a small magnet and will induce 
NMR changes in water molecules and then will be detected by MRI. Some MRI contrast 
agents include dotarem 60 and teslascan 61 based on Gd and Mn  respectively (Figure 
1.34).77  
 
  
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.34. MRI contrast agents, dotarem 60 and teslascan 61. 
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A number of compounds from the Meggers group show promise as selective 
kinase inhibitors. They propose the role of metals as “hypervalent carbon”, enabling 
octahedral coordination for example and enabling interactions with the kinase pocket that 
are not possible with tetrahedral carbon.83  
 
The pyridocarbazole platinum complex has been synthesized to mimic the 
structure of staurosporine, which is a natural product that is isolated from bacterium and 
it also had the anti-fungal, anti-hypertensive activities, inhibitor protein kinase and so 
on.84  Staurosporine acts as a kinase inhibitor, by binding to the ATP-binding site on the 
kinase instead of ATP, stopping phosphorylation. However, staurosporine is unselective 
and could not be used as a drug as it needs to be more specific since it binds to a number 
of the 500+ kinases present in the body. Figure 1.35 shows a Pt-staurosporine complex 
62, which shows high affinity binding to glycogen synthase kinase 3 (GSK-3α).85 
 
 
 Figure 1.35. Pt-staurosporine complex 62. 
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 Ruthenium complex (SPM1) 63 (Figure 1.36) has been synthesized and its study 
shown against acetylcholinesterase (AChE) with an IC50 of 200 nM compared to the 
parent compound [Ru(phen)3]Cl2 (IC50 of 10 µM). AChE is an enzyme which catalyzes 
the breakdown of acetylcholine and some other choline esters and is related to 
neurotransmitters.86-87   
 
 
Figure 1.36. Structure of SPM1, 63. 
 
 Another protein kinase inhibitor based on octahedral iridium (Ir) complex 64 
(Figure 1.37) has been synthesized and studied for it angiogenesis properties, which is 
related with the growth of new blood vessels. It showed a remarkable selectivity for 
VEGFR3 (vascular endothelialgrowth factor receptor 3) over other protein kinases.88   
 
 
 
 
 
 
 
 
 
 
Figure 1.37. Octahedral Ir complex 64. 
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The applications of metals in medical uses are increasing either via the design of 
new ligands or of metal-based complexes. Normally, therapeutic agents and drugs will be 
tested in in vitro to provide initial information about cytotoxicity (preliminary data) then 
in vivo assays will provide the pharmacokinetics data, these 2 steps are called “preclinical 
step”. The next step will be “clinical trials” which consist of phase I, II, III and IV, these 
steps are concerned with dosage, safety and efficacy. The two-last steps will be FDA 
review and FDA post-market safety monitoring (U.S. Food & Drug Administration). 
Typically, a drug costs over $1 billion to develop and it takes 10-15 years. 
Scheme 1.2. The drug development process. 
 
There are now many metal compounds that have been used as therapies or reached  
clinical trials such as carboplatin,1 arsenic trioxide,89 gallium nitrate,90 NAMI-A, 
KP1019,91 BEOV,77 ferroquine92 and so on. The structure of those compounds is shown 
in Figure 1.38.77 
 
Carboplatin1 is a chemotherapy drug containing platinum metal used to treat 
some cancers including lung, brain, breast, ovarian, testicular, bladder, head and neck. It 
is used by intravenous injection. Side effects of carboplatin include nausea, low blood 
cell levels and allergic reactions to the body.  
 
Arsenic trioxide or Trisenox®89 is anticancer drug for acute promyelocytic 
leukemia (APL), it is administered via an intravenous injection. 
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 Gallium nitrate90 is a drug which used for treating symptomatic hypercalcemia 
(hypercalcemia associated with cancer). 
 
NAMI-A (New Anti-Tumor Metastasis Inhibitor)91 is a compound based on 
ruthenium metal and now has entered to the clinical trials phase II. It used for treatment 
of metastatic cancer. Side effects are nausea, vomiting, diarrhea, fatigue, inflammation in 
mouth and lips, fever, etc. It is thought to act as a prodrug to Ru(II) in hypoxic (low 
oxygen) solid tumours. 
KP1019 or trans-[tetrachlorobis(1 H-indazole)ruthenate(III)]91 is also based 
on ruthenium metal and has been to clinical trials phase I. It is used for metastatic cancer 
and shown potent cytotoxicity against colorectal cancer. 
 BEOV or bis(ethylmaltolato)oxovanadium(IV)77 is based on vanadium metal 
and has entered clinical trials phase II. It is used to treat diabetes. In clinical trials phase 
I, it has been given orally to non-diabetic volunteers and the results showed no side 
effects. 
 
 Ferroquine (FQ)92 is a compound containing with ferrocene and has entered 
clinical trials phase II. It is used as an antimalarial agent. 
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Figure 1.38. Structures of some metal complexes in medicine. 
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1.6 Conclusions 
 
 
Above, an overview of some uses of metals in medicinal chemistry has been 
provided, focussing mainly on ferrocene-based chemistry. This is certainly an area of 
vibrant research activity but, unfortunately, due to space restraints, only a small amount 
of this chemistry has been mentioned. Hereafter, the study of ferrocene as a bioisostere 
of aryl and bulky alkyl groups is presented, supported by solid state (x-ray) studies and 
biological assays. In many cases nM or submicromolar ferrocene-based metallo-drugs or 
bioorganometallic complexes are described. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.39. Ferrocene bioisostere principle used in this thesis. 
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Chapter 2 
Synthesis of CB2 agonists and FAAH inhibitors 
containing a ferrocene unit. 
2.1 Overview 
 Ferrocenylamine has been explored as a bioisostere1 of bulky amines in a series 
of potential CB1 and CB2 (cannabinoid) receptor agonists. A series of ferrocene analogues 
has been synthesized by the amide coupling reaction of aminoferrocene with carboxylic 
acid-functionalised isoxazole, quinolinone and pyridinone rings as CB2 agonists and their 
application as potent FAAH (fatty acid amide hydrolase) inhibitors has been studied. The 
products were characterized by elemental analyses, NMR spectroscopy, mass 
spectrometry, LC-MS and, many were further analysed by X-ray crystallographic studies. 
Ferrocene analogues of known bioactive adamantylamides were found to be effective 
cannabinoid receptor (CB1 and CB2) agonists, with low nanomolar potency. X-ray 
crystallography showed intramolecular hydrogen bonding to be important for activity as 
N-methylation of the amide resulted in the loss of hydrogen bonding and biological 
activity. Biological studies were undertaken through a collaboration with a medicinal 
chemistry group in Lille, France, who recently published work on FAAH inhibitors and 
CB2 agonists,
2-3 where they found that bulky amine substituents were beneficial for 
biological activity.4  
 
2.2 Introduction 
 G protein-coupled receptors (GCRs) are an important and large group of 
therapeutic targets. They play a central role in many biological processes and are linked 
to a wide range of disease areas. The GPCR-G-protein activation/deactivation cycle5 is 
shown in Scheme 2.1. 
37 
 
Figure 2.1. GPCR-G-protein activation/deactivation cycle 
                              (Licensed under a Creative Commons Distribution by Repapetilto). 
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About 20-30% of drugs in the market act on GPCRs6-7 such as ranitidine, salbutamol, 
chlorpromazine, doxepin, cinnarizine and so on. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Some medications acting on GPCRs. 
 
Cannabinoid receptors are also  receptors that belong to the GPCR family, and 
contain two different subtypes CB1 and CB2 (both are in the endocannabinoid system), 
CB1 is found mainly in central nervous system while CB2 is found in the immune system.
8 
Known endocannabinoids that are involved in a variety of physiological processes such 
as pain sensation, mood and memory include N-arachidonoyl ethanolamine (anandamide, 
AEA)9 which acts as a ligand of central CB1 cannabinoid receptors and has also been  
shown to be a potent and selective inhibitor of the proliferation of human breast cancer 
cells that can activate the cannabinoid receptor.10 Arachidonoylglycerol (2-AG)11-12  also 
acts as a ligand for the cannabinoid CB1 receptor.
13    
 
    
 
 
 
 
Figure 2.3. The molecular structures of AEA and 2-AG. 
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CB2 receptors have been proposed to have a significant role in inflammation.
14 
Overexpression of CB2 receptors was found after an inflammation stimulus.
15 Activation 
of CB2 receptors occurred with the suppression of macrophage activation, the blockage 
of calcium signals in nociceptors (these are sensory nerve cells which relay signals to the 
spinal cord and brain upon possible damage or stimuli), and the modulation of nociceptor 
excitability, related to anti-inflammation, neuroprotection, gastroprotection, or other 
protective effects.16 The CB2 receptor is coupled to a Gαi/0 signalling target which inhibits 
adenylyl cyclase (AC is an enzyme and there are ten known isoforms of adenylyl cyclases 
in mammals) and cyclic adenosine monophosphate 65 (cAMP is a derivative of ATP and 
important for the intracellular signal transduction) production.17 Ligands for CB2 
receptors can be classified as agonists, antagonists and inverse agonists when agonists 
activate CB2 receptors and then repress adenylyl cyclase resulting in a decrease in cAMP 
concentration, antagonists prevent the activation of receptors by endocannabinoids, and 
inverse agonists reduce CB2 receptor activity and induce an accumulation of cAMP 
through upregulation of adenylyl cyclase activity.18  
 
 
   
 
 
 
 
 
Figure 2.4. The molecular structures of ATP and cAMP 65. 
CB2 agonists have been described to produce anti-inflammatory, analgesic, and 
other protective efficacies by the modulation of calcium signal and nociceptor 
excitability.16,19 CB2 antagonists/inverse agonists showed potential in the treatment of 
bone-dependent disorders (such as osteoporosis) through regulation of bone 
proliferation.20-21 In addition, inverse agonists have been identified to exert 
immunomodulatory (capable of modifying or regulating one or more immune functions) 
ability and therapeutic potential for inflammation through regulating the migration of 
inflammatory cells and immune cells, including leukocytes (white blood cells).22-23 
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CB2 ligands have been observed as an interesting approach for the treatment of a 
range of nervous or immune system disorders. Over the last decades, research on CB2 
ligands has significantly progressed. Several CB2 agonists, antagonists, and inverse 
agonists have been described. WIN 55,212-2 or (R)-(+)-[2,3-Dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone, 
66, one of the most potent dual CB1/CB2 agonists, has been widely used for the 
investigation of cannabinoid-receptor-dependent biological responses.24 It exerts 
antinociceptive efficacy in a model of spinal cord injury and inhibits the proliferation of 
cancer cells.25-26 (2-Iodo-5-nitrophenyl)-[1-[(1-methylpiperidin-2-yl)methyl]indol-3-
yl]methanone, 67 (AM-1241), an aminoalkylindole derivative, has been shown to act as 
a potent selective CB2 agonist and shows efficacy in a variety of in vivo pain and 
inflammation models, including spinal nerve ligation (SNL)-induced nociception and 
2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis.27 Molecule 68 (SR144528) 
was the first selective CB2 antagonist, discovered by Sanofi Research, and was later 
identified to possess temperature-dependent inverse agonist properties.28 It was further 
identified to upregulate the expression of CB2 receptors.
29-30 6-Iodopravadoline, 69 
(AM630), a potent selective CB2 inverse agonist, showed potential to attenuate titanium-
particle-induced osteoporosis.31-32 Two other well-known CB2 inverse agonists, 70 
(Sch225336) and 71 (Sch414319), can relieve inflammation by modulating the migration 
of immune cells.20-23 
 
 
Figure 2.5. Structures of some well-known CB2 ligands. 
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4-Oxo-1,4-dihydropyridine and 4-oxo-1,4-dihydroquinoline have been 
synthesized as potent CB2 agonists or inverse agonists.
33-34 Actually, derivatives with a 
1-adamantylamine group were noted to be potent and functionally selective CB2 ligands. 
For instance, the 4-oxo-1,4-dihydroquinoline derivative 72 was identified as a CB2 
agonist (Ki = 16.4 nM, Emax(GTPγS) = 125.6%). In the 4-oxo-1,4-dihydropyridines series, 
derivative 73 showed partial agonist properties, while compound 74 was identified as a 
full agonist for CB2 receptors (Ki = 20 and 29 nM, Emax(GTPγS) = 148% and 212%, EC50 
(GTPγS) = 5.5 and 12.2 nM, respectively). These compounds showed good selectivity 
over CB1 receptors (selectivity index (SI) > 100).
35-36 Another 4-oxo-1,4-dihydropyridine 
derivative, 75 (Ki = 4 nM, Emax(GTPγS) = 39%, EC50(GTPγS) = 3.2 nM, SI = 148), 
containing a phenyl ring rather than an alkyl group at the C6 position, acts as a CB2 
inverse agonist.35 Depending on the substituent at position-6 (methyl, tert-butyl, or phenyl 
group), the biological response changed from CB2 agonist to CB2 inverse agonist.
35 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. 4-Oxo-1,4-dihydropyridine/4-oxo-1,4-dihydroquinolinone derived   
        CB2 ligands containing an adamantylamine group. 
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Fatty acid amide hydrolase (FAAH) is an enzyme that hydrolyses fatty acid 
derivatives such as anandamide (AEA), palmitoylethanolamide (PEA) or 
oleoylethanolamide (OEA).37 Enzymatic activity was described in the 1960s showing it 
to produce ethanolamine38 but the role of FAAH in hydrolyzing anandamide was first 
reported in 1993.39 
 
 
 
Scheme 2.1. The hydrolysis of AEA by FAAH. 
 
 
Elevated levels of AEA are known to offer protection in inflammation. Hence, 
preventing its removal, by inhibiting FAAH, could be a useful approach in treating 
diseases including IBS (Irritable Bowel Syndrome) and other disorders such as colitis. 
Figure 2.7 shows the structure of FAAH inhibitors reported by others. URB597 is 
particularly active against acute, inflammatory disorders and protects against 
experimental colitis40 and OL-135 is described as a potent FAAH inhibitor.41  
 
 
 
 
 
Figure 2.7. Literature FAAH inhibitors. 
 
 
 
 
 
 
 
 
43 
 
New FAAH inhibitors based on a 3-carboxamido-5-aryl-isoxazole scaffold have 
been synthesized by our collaborator (Millet group). Results showed that compounds 76 
and 77 inhibit the development of dextran sulfate sodium (DSS)-induced acute colitis in 
mice.2  
 
 
 
 
 
 
 
 
 
 
Figure 2.8. FAAH inhibitors 76 and 77. 
 
Ferrocene, an organometallic complex, shows advantageous properties for the 
design of potential pharmaceutical agents. For instance, its lipophilicity (logP = 2.66 for 
ferrocene vs 2.69 for adamantane)42 endows its derivatives with suitable bioavailability 
and membrane penetration.43-44 The rotation of the aromatic cyclopentadienyl ring 
confers conformational diversity on ferrocene (staggered or overlapped conformation), 
which is favourable for orientating ferrocene-derived ligands into their receptor pockets.45 
Additionally, ferrocene derivatives have been identified to produce a variety of biological 
responses, including anticancer,46-47 antimalarial,48 antioxidant,49 antibacterial,50 and 
glucose-sensing properties.51 Thus, development of ferrocene derivatives could be 
regarded as an interesting approach to discover potential novel pharmaceutical agents and 
tool compounds. 
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2.3 Results and Discussion 
On the basis of these interesting literature results, we decided to observe the 
influence of the replacement of the 1-adamantyl group by a bulky, lipophilic, potentially 
ferrocene unit bioisostere (Figure 2.9) in terms of synthetic and biological potential. 
 
 
 
 
 
 
 
 
 
 
Figure 2.9. A ferrocenylamine replacement of a 1-adamantylamine group. 
 
Herein, we report the synthesis and biological evaluation of a novel series of 
ferrocenyl 4-oxo-1,4-dihydropyridine and dihydroquinoline derivatives and 3-
carboxamido-isoxazole derivatives (Scheme 2.2). All series of compounds were easily 
synthesized by standard amide coupling protocols and were characterized by 1H and 13C 
NMR spectroscopy, mass spectrometry, and combustion analysis, for solids, or by 
percentage purity by LCMS for oils. In the case of solids, six of these air-stable 
derivatives were further characterized in the solid state by X-ray crystallography, some 
of them confirming the presence of an intramolecular hydrogen bond between the ketone 
and amide functionalities (Figure 2.10), which is also observed in solution-based studies 
(δ = ca. 11.5 ppm in their 1H NMR spectra) and the 1H NMR spectrum of isoxazole 
compounds showed the most downfield signal was assigned to the –NH amide ( 7.50-
8.00 ppm) located next to the heterocyclic ring. The results from elemental analysis and 
mass spectrometry corresponded to the calculated values and the solid state molecular 
structures of compounds were determined by X-Ray crystallography (Figure 2.11).   
 
 
 
45 
 
 
 
 
Scheme 2.2. Synthesis of ferrocenylamides.  
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 Often, an intramolecular hydrogen bond acts as a conformational lock, stabilizing 
an active conformation of a molecule and improving its binding to a receptor or enzyme.52  
 
 
 
 
 
 
   
 
 
 
 
 
 
     
 
 
 
 
 
 
Figure 2.10. X-ray structures of 78, 79 and 80.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11. X-ray structures of 84 and 85.   
 
 
 
 
 
78 
79 80 
  
84 85 
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We then decided to synthesize a N-Me amide derivative 87 to compare its receptor 
binding to its NH-amide precursor 78, and hence the role of intramolecular hydrogen 
bonding on receptor binding. We confirmed its structure by X-ray crystallography, which 
clearly shows a change of molecular structure by the loss of the intramolecular H-bond 
(Scheme 2.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.3. N-Methylation reaction of 78 and X-ray structure of 87.  
 
 
 
 
 
 
 
 
 
 
87 
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The 1H NMR spectrum of 87, even at variable temperature, showed a broad signal 
and was indicative of a fluxional molecule, but could also be due to the increased 
solubility of compound when the temperature is raised (Figure 2.12).  
 
 
 
Figure 2.12. 1H NMR spectrum of 87 in CDCl3 at 20 C and 37 C.   
 
 
 
 
 
 
 
T = 20 C 
 
T = 37 C 
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2.4 Biological Results 
The affinities of each synthesized compound for both CB1 and CB2 receptors were 
determined by a competitive radioligand displacement assay using the dual CB1/CB2 
ligand [3H]-CP55,940.53,3 Compounds 78, 79, 80, 81, 82, and 83 (Scheme 2.2) showed 
good CB2 affinity (5 nM < Ki < 220 nM). Specifically, for the 4-oxo-1,4-dihydroquinoline 
derivatives, a lipophilic alkyl chain on the endocyclic nitrogen (78, Ki = 36.7 nM; 77, Ki 
= 10.9 nM) gives a superior affinity to the compound compared with a hydrophilic 
morpholinoethyl group (80, Ki = 133.6 nM). As expected, the methylation of the amide 
group of compound 78 brought about a sharp decrease in affinity for CB2 (87, Ki > 1 μM). 
In the 4-oxo-1,4-dihydropyridine series, a bulky group (such as a tert-butyl or a phenyl 
group, 82, Ki = 59.5 nM, and 83, Ki = 5.2 nM, respectively) is preferred for CB2 affinity 
rather than a small alkyl group (such as a methyl, 81, Ki = 218.8 nM) at the C6 position. 
Compared to previously developed CB2 ligands (such as 72, 73, 74, and 75, SI > 100), 
the replacement of the 1-adamantyl group by a ferrocene seems to maintain the CB2 
affinity of the molecules, with only a weak decrease in affinity for 81 compared to 73. 
However, it brings about an obvious increase in affinity for CB1 receptors (81, 82, and 
83, SI < 15). 
 
Compounds displaying potent CB2 affinity were further studied for their 
functionality by cAMP assays in Chinese hamster ovary cells (CHO) expressing CB2 
receptors (CHO-CB2).
54-55 Cells were treated with forskolin, 88 in order to activate 
adenylyl cyclase and cAMP production. In Table 2.1, the maximum efficacy (Emax) of a 
compound represents the maximum response at 10−6 M and is expressed as the percentage 
of forskolin-induced cAMP production. Compound potency was also evaluated in the 
presence of increasing concentrations of each compound and was expressed as the 
concentration that exhibits the half-maximal response (EC50). Although 4-oxo-1,4- 
dihydroquinolines 78 and 79 were determined to show potent affinity for CB2 receptors, 
their binding to the receptors did not significantly affect CB2-mediated regulation of 
cAMP production (Emax cAMP = 74% and 78%, respectively). The replacement of the N-
substituted alkyl group of 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives by an 
N-ethyl morpholine gave rise to an obvious increase in CB2 agonist functionality of the 
molecule (80, Emax cAMP = 52%), which might be attributed to probable hydrogen-
binding interactions between morpholine and CB2 receptors. The 4-oxo-1,4- 
50 
 
dihydropyridine-3-carboxamide derivatives bearing an alkyl substituent at the C6 
position (81 and 82) show CB2 agonist properties (Emax cAMP = 50% and 55%, 
respectively). In the 4-oxo-1,4-dihydropyridine-3-carboxamide series, compound 83 
(Emax cAMP = 500%), bearing a 6-substituted phenyl group instead of an alkyl 
substituent, appears to behave as a CB2 inverse agonist. These observations are consistent 
with the previous published results.14 83-induced accumulation of cAMP (EC50 cAMP = 
12 nM) is approximately 65-fold greater than for compound 69 (EC50 cAMP = 785 nM), 
one of the most potent CB2 inverse agonists reported to date. Interestingly, as illustrated 
in Table 2.1, replacement of the 1-adamantyl group (73, 74, and 75) by a ferrocene (81, 
82, and 83) does not alter the functionality of these compounds and their ability to regulate 
cAMP formation. Of the isoxazole series only compound 85 displayed activity, in the ca. 
30 nM range. 
 
 
 
 
 
 
 
 
 
 
Figure 2.13. Structure of forskolin, 88.   
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The cytotoxicity of these compounds was determined at 10 μM using a cell 
proliferation assay on Chinese hamster ovary cells wild type (CHO-WT), CHO-CB2, and 
human colorectal adenocarcinoma cells HT29. No significant cytotoxicity was observed 
for these new compounds except for derivative 80, which slightly inhibited the 
proliferation of HT29 cells (48% at 10 μM).56 
 
The affinities (Ki Values), Maximum Efficacy (Emax), and/or Half-Maximal 
Response (EC50) of compounds 73−75, 78−80, 81−83, 87, and reference compounds 
(WIN-55,212-2, AM630) toward hCB2 and hCB1 Cannabinoid Receptors, Selectivity 
Ratios hCB2 versus hCB1, and Cytotoxicity on CHO-WT, CHO-CB2, and HT29 Cells are 
shown in Table 2.1.  
We are awaiting FAAH biological studies of 84, 85 and 86 from our Lille-2 
University partners to establish: i) if the bioisostere changes lead to retention or loss of 
biological activities and ii) if other analogues need to be made, once SAR (structure 
activity relationship) has been established. 
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2.5 Conclusion 
A series of ferrocenylamine-based 4-oxo-1,4-dihydropyridine and 
dihydroquinoline derivatives has been synthesized. Many display potency even at low 
(nM) concentrations vs CB1 and CB2 receptors. A crucial intramolecular (NH---O=C) 
hydrogen bond, evidenced in both solution and the solid state, appears to be important for 
receptor binding since N-methylation, and loss of this hydrogen bond, leads to a loss of 
affinity. This study demonstrates that aminoferrocene-based compounds can replace 
adamantanyl amines in GPCR-targeting bioorganometallic agents.57 Whether or not this 
effect is simply a size/shape similarity of a ferrocene moiety compared to an adamantyl 
group or if there is the induction of reactive oxygen species (ROS), as is often the case 
with ferrocenyl groups in bioorganometallic chemistry, is beyond the scope of this study, 
but the latter cannot be ruled out.58,59,60 
 
2.6 Experimental 
The acids precursors for making compound 76-84 were provided by our Lille-2 
University partners, solvents and reagents were purchased from commercial suppliers and 
were used without purification. Ferrrocenylamine was purchased from TCI, UK and used 
as such. All reactions were performed in a fume hood. 1H, 13C-NMR spectra were 
recorded on Varian 500 MHz or 400 MHz spectrometers and chemical shifts are reported 
in ppm, usually referenced to TMS as an internal standard. LCMS were performed on a 
5 μm C18 110 Å column and percentage purities were ran over 30 minutes in 
water/acetonitrile with 0.1% formic acid (5 min at 5%, 5%-95% over 20 min, 5 min at 
95%) with the UV detector at 254 nm. High resolution mass spectrometry (HRMS) were 
performed by the EPSRC National Mass Spectrometry Facility, University of Swansea. 
Elemental analyses were conducted by Stephen Boyer (London Metropolitan University). 
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1-Cyclohexyl-N-ferrocenyl-4-oxo-1,4-dihydroquinoline-3-carboxamide, 78.  
The title compound was prepared by a coupling reaction; 1-cyclohexyl-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (271 mg, 1 mmol) was reacted with 1-
Hydroxybenzotriazole (HOBT) (68 mg, 0.5 mmol), O-(benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (HBTU) (570 mg, 1.5 mmol), and N,N-
Diisopropylethylamine (DIPEA) (0.35 mL) in CHCl3 solution (20 mL). The reaction 
mixture was stirred at RT for 45 min, and then aminoferrocene (241 mg, 1.2 mmol) was 
added and the mixture was stirred for 24 h. Afterward, the reaction mixture was washed 
with NaOH (0.5 N, 20 mL), HCl (1 N, 20 mL), and H2O (20 mL). The organic layer was 
dried with MgSO4 and evaporated to a 3 mL volume and purified by column 
chromatography. The orange band was eluted with a hexane/ethyl acetate (7:3) mixture 
and was collected and evaporated to dryness. The yield was 340 mg, 75% (orange solid). 
Crystallization by diffusion between CH2Cl2 and hexane provided orange crystals.  
1H NMR (CDCl3, 500 MHz): δ =11.56 (1H, s, NH), 9.04 (1H, s, CH), 8.62 (1H, dd, J = 
8.1,1.6, CH), 7.78−7.76 (1H, m, CH), 7.68 (1H, d, J = 8.7, CH), 7.55−7.53 (1H, m, CH), 
4.82 (2H, d, J= 1.8, 2CH), 4.53−4.51 (1H, m, CH), 4.19 (5H, s, Cp), 4.05 (2H, d, J = 1.8, 
2CH), 2.22−2.19 (2H, m, CH2), 2.08−2.05 (2H, m, CH2), 1.89−1.86 (3H, m,CH2+ CH), 
1.60−1.57 (2H, m, CH2), 1.36−1.34 (1H, m, CH).  
 
13C NMR (CDCl3, 126 MHz): δ = 176.2, 163.2, 143.1, 139.4, 132.8, 128.1, 127.6, 125.0, 
115.2, 111.8, 94.5, 69.2, 64.5, 61.8, 59.8, 32.8, 25.9, 25.2.  
 
HRMS-ESI (m/z): found 455.1396, calcd for [C26H26FeN2O2 + H]
+ 455.1416. 
 
Anal. Calcd (%) for C26H26FeN2O2: C, 68.73; H, 5.77; N, 6.17.  
Found (%): C, 68.50; H, 5.89; N, 6.06. 
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N-Ferrocenyl-4-oxo-1-pentyl-1,4-dihydroquinoline-3-carboxamide, 79. 
4-Oxo-1-pentyl-1,4-dihydroquinoline-3-carboxylic acid (25.9 mg, 0.1 mmol) was reacted 
with HOBt (6.8 mg, 0.05 mmol), HBTU (57 mg, 0.15 mmol), and DIPEA (0.035 mL) in 
CHCl3 solution (2 mL). The reaction mixture was stirred at RT for 45 min, and then 
aminoferrocene (24.1 mg, 0.12 mmol) was added and the mixture was stirred for 24 h. 
Workup was as above. The orange band was eluted with a hexane/ethyl acetate (1:1) 
mixture and was collected and evaporated to dryness. The yield was 19 mg, 43% (orange 
solid). Crystallization by diffusion between CH2Cl2 and hexane provided yellow crystals.  
 
1H NMR (CDCl3, 500 MHz): δ = 11.51 (1H, s, NH), 8.84 (1H, s, CH), 8.61−8.58 (1H, m, 
CH), 7.79−7.77 (1H, m, CH), 7.54−7.52 (2H, m, Ar), 4.81 (2H, d, J = 1.9, 2CH), 
4.30−4.27 (2H, m, CH2), 4.20 (5H, s, Cp), 4.05 (2H, d, J = 1.9, 2CH), 1.42−1.38 (6H, m, 
3CH2), 0.94−0.90 (3H, m, CH3).  
 
13C NMR (CDCl3, 126 MHz): δ = 176.6, 163.1, 147.4, 139.0, 132.9, 128.0, 127.5, 125.2, 
115.9, 111.9, 94.4, 69.2, 64.6, 62.0, 54.4, 28.7, 28.8, 22.2, 13.8.  
 
HRMS-ESI (m/z): found 443.1412, calcd for [C25H26FeN2O2 +H]
+ 443.1416.  
 
Anal. Calcd (%) for C25H26FeN2O2: C, 67.88; H, 5.92; N, 6.33.  
Found (%): C, 67.87; H, 6.05; N, 6.45. 
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N-Ferrocenyl-1-(2-morpholinoethyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide, 
80.  
1-(2-Morpholinoethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (30.2 mg, 0.1 
mmol) was reacted with HOBt (6.8 mg, 0.05 mmol), HBTU (57 mg, 0.15 mmol), and 
DIPEA (0.035 mL) in CHCl3 solution (2 mL). The reaction mixture was stirred at RT for 
45 min, and then aminoferrocene (24.1 mg, 0.12 mmol) was added and the mixture was 
stirred for 24 h. Workup was as above. The orange band was eluted with a hexane/ethyl 
acetate (3:7) mixture and was collected and evaporated to dryness. The yield was 23 mg, 
47% (yellow solid). Crystallization by diffusion between acetone and hexane provided 
orange crystals.  
 
1H NMR (CDCl3, 500 MHz): δ= 11.46 (1H, s, NH), 8.84 (1H, s, CH), 8.60 (1H, dd, J = 
8.1,1.5, CH), 7.79−7.76 (1H, m, CH), 7.58−7.54 (2H, m, Ar), 4.82-4.79 (1H, m, CH), 
4.39 (2H, d, J = 1.9, 2CH), 4.20 (5H, s, Cp), 4.13−4.11 (1H, m, CH), 4.08−4.05 (1H, m, 
CH), 3.70−3.68 (2H, m, CH2), 2.85−2.83 (1H, m, CH), 2.53 (2H, m, CH2), 2.05 (1H, s, 
CH), 1.29−1.26 (3H, m).  
 
13C NMR (CDCl3, 126 MHz): δ = 176.6, 162.9, 148.2, 139.0, 133.0, 128.0, 127.6, 125.2, 
115.6, 111.8, 94.3, 69.2, 66.8, 64.6, 62.0, 56.5, 53.8, 51.4.  
 
HRMS-ESI (m/z): found 486.1471, calcd for [C26H27FeN3O3 + H]
+ 486.1475.  
 
Anal. Calcd (%) for C26H27FeN3O3: C, 64.34; H, 5.61; N, 8.66.  
Found (%): C, 64.27; H, 5.54; N, 8.63. 
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N-Ferrocenyl-6-methyl-4-oxo-1-pentyl-1,4-dihydropyridine-3-carboxamide, 81. 
6-Methyl-4-oxo-1-pentyl-1,4-dihydropyridine-3-carboxylic acid (22.3 mg, 0.1 mmol) 
was combined with HOBt (6.8 mg, 0.05 mmol), HBTU (57 mg, 0.15 mmol), and DIPEA 
(0.035 mL) in CHCl3 (2 mL). The reaction mixture was stirred at RT for 45 min, and then 
aminoferrocene (24.1 mg, 0.12 mmol) was added. Workup was as above. The orange 
band was eluted with a hexane/ethyl acetate (2:3) mixture and was collected and 
evaporated to dryness. The yield was 21 mg, 52% (orange oil).  
 
1H NMR (CDCl3, 500 MHz): δ = 11.72 (1H, s, NH), 8.45 (1H, s, CH), 6.46 (1H, s, CH), 
4.88−4.84 (2H, m, CH2), 4.24 (5H, s, Cp), 4.15−4.12 (2H, m, 2CH), 3.91 (2H, d, J = 1.9, 
2CH), 2.39 (3H, s, CH3), 1.80−1.76 (2H, m, CH2), 1.38−1.32 (4H, m, 2CH2), 0.94−0.90 
(3H, m, CH3).  
 
13C NMR (CDCl3, 126 MHz): δ = 177.4, 162.4, 147.8, 144.9, 121.4, 118.9, 69.6, 65.0, 
62.0, 53.9, 30.6, 29.7, 28.5, 22.2, 19.0, 13.8. 
 
HRMS-ESI(m/z): found 407.1414, calcd for [C22H26FeN2O2 + H]
+ 407.1416.  
 
LCMS purity (UV) = 100%, tR 19.13 min. LCMS purity (positive ion, TIC) = 93.5%, tR 
19.20 min. 
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6-tert-Butyl-N-ferrocenyl-4-oxo-1-pentyl-1,4-dihydropyridine-3-carboxamide, 82.  
6-(tert-Butyl)-4-oxo-1-pentyl-1,4-dihydropyridine-3-carboxylic acid (26.5 mg, 0.1 
mmol) was combined with HOBt (6.8 mg, 0.05 mmol), HBTU (57 mg, 0.15 mmol), and 
DIPEA (0.035 mL) in CHCl3 (2 mL). The reaction mixture was stirred at RT for 45 min, 
and then aminoferrocene (24.1 mg, 0.12 mmol) was added and the mixture was stirred 
for 24 h. Workup was as above. The orange band was eluted with a hexane/ethyl acetate 
(1:1) mixture, which was collected and evaporated to dryness. The yield was 22 mg, 49% 
(orange oil).  
 
1H NMR (CDCl3, 500 MHz): δ = 11.70 (1H, s, NH), 8.48 (1H, s, CH), 6.66 (1H, s, CH), 
4.78−4.76 (2H, m, 2CH), 4.16 (5H, s, Cp), 4.13−4.10 (2H, m, 2CH) 4.04−4.02 (2H, m, 
CH2), 2.19−2.15 (2H, m, CH2), 1.46 (9H, s, t-Bu), 1.42−1.38 (4H, m, 2CH2), 0.98−0.92 
(3H, m, CH3).  
 
13C NMR (CDCl3, 126 MHz): 177.7, 162.4, 158.5, 147.0, 119.0, 118.2, 110.0, 94.0, 69.2, 
64.6, 62.1, 59.5, 54.9, 35.8, 32.0, 30.4, 28.7, 22.2, 13.9.  
 
HRMS-ESI(m/z) found 449.1886, calcd for [C25H32FeN2O2 + H]
+ 449.1886. 
 
LCMS purity (UV) = 100%, tR 23.68 min. LCMS purity (positive ion, TIC) = 96.8%, tR 
23.76 min. 
 
 
 
 
 
 
59 
 
 
 
 
 
 
 
 
 
N-Ferrocenyl-4-oxo-1-pentyl-6-phenyl-1,4-dihydropyridine-3-carboxamide, 83.  
4-Oxo-1-pentyl-6-phenyl-1,4-dihydropyridine-3-carboxylic acid (28.5 mg, 0.1 mmol) 
was reacted with HOBt (6.8 mg, 0.05 mmol), HBTU (57 mg, 0.15 mmol), and DIPEA 
(0.035 mL) in CHCl3 (2 mL). The reaction mixture was stirred at RT for 45 min, and then 
aminoferrocene (24.1 mg, 0.12 mmol) was added and the mixture stirred for 24 h. Workup 
was as above. The orange band was eluted with a hexane/ethyl acetate (1:1) mixture, 
which was collected and evaporated to dryness. The yield was 29 mg, 62% (orange solid). 
 
1H NMR (CDCl3, 500 MHz): δ = 11.80 (1H, s, NH), 8.61 (1H, s, CH), 7.56−7.52 (3H, m, 
Ar), 7.39−7.35 (2H, m, Ar), 6.54 (1H, s, CH), 4.80 (2H, d, J = 1.9, 2CH), 4.20 (5H, s, 
Cp), 4.05 (2H, d, J = 1.9, 2CH), 3.85−3.83 (2H, m, CH2), 1.65−1.61 (2H, m, CH2), 
1.18−1.16 (4H, m, 2 CH2), 0.81 (3H, t, J = 7.1, CH3).  
 
13C NMR (CDCl3, 126 MHz): δ = 177.1, 162.4, 151.8, 144.8, 133.2, 130.1, 129.0, 128.5, 
122.4, 119.4, 93.9, 69.2, 64.7, 62.1, 54.4, 30.6, 28.2, 21.9, 13.7.  
 
HRMS-ESI(m/z): found 469.1576, calcd for [C27H28FeN2O2 + H]
+ 469.1573. 
 
Anal. Calcd (%) for C27H28FeN2O2: C, 69.24; H, 6.03; N, 5.98.  
Found (%): C, 68.89; H, 6.13; N, 5.81. 
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5-Methyl-N-ferrocenylisoxazole-3-carboxamide, 84.  
The title compound was prepared by a coupling reaction. 5-Methylisoxazole-3-carboxylic 
acid (127 mg, 1 mmol) was reacted with HOBt (68 mg, 0.5 mmol), HBTU (570 mg, 1.5 
mmol) and DIPEA (0.35 mL). in CHCl3 (20 mL). The reaction mixture was stirred at RT 
for 45 min. and then aminoferrocene (241 mg, 1.2 mmol) was added and the mixture was 
stirred for 24 hr. Workup was as above. During flash chromatography, the orange band 
was eluted with a hexane: ethyl acetate (6:4) mixture, which was collected and evaporated 
to dryness. The yield was 160 mg, 45% (orange solid). Crystallization by diffusion 
between CH2Cl2 and hexane provided the orange crystals. 
 
1H NMR (CDCl3, 500 MHz): δ = 7.90 (1H, s, NH), 6.50 (1H, s, Ar), 4.72-4.69 (2H, m, 
2CH), 4.20 (5H, s, Cp), 4.07-3.97 (2H, m, 2CH), 2.52 (3H, s, CH3).  
 
13C NMR (CDCl3, 126 MHz): δ = 171.5, 158.8, 156.9, 101.4, 93.3, 76.7, 69.3, 64.9, 61.6, 
12.4.  
 
HRMS-ESI(m/z): found 311.0471, calcd. for [ C15H14FeN2O2 + H]
+  311.0477.  
 
Anal. Calcd (%) for C15H14FeN2O2: C, 58.09; H, 4.55; N, 9.03.  
Found (%): C, 58.20; H, 4.63; N, 9.13. 
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5-(2-(Pentyloxy)phenyl)-N-ferrocenylisoxazole-3-carboxamide, 85.                         
The title compound was prepared by a coupling reaction. 5-(2-
(Pentyloxy)phenyl)isoxazole-3-carboxylic acid (27.5 mg, 0.1 mmol) was reacted with 
HOBt (6.8 mg, 0.05 mmol) , HBTU (57 mg, 0.15 mmol) and DIPEA (0.035 mL). in 
CHCl3 (2 mL). The reaction mixture was stirred at RT for 45 min. and then added 
aminoferrocene (24.1 mg, 0.12 mmol) stirred for 24 hr. Workup was as above. The orange 
band was eluted with a hexane: ethyl acetate (1:1) mixture, which was collected and 
evaporated to dryness. The yield was 34 mg, 70% (orange solid). Crystallization by 
diffusion between CH2Cl2 and hexane provided the orange crystals. 
 
1H NMR (CDCl3, 500 MHz): δ = 8.00-7.80 (2H, m, Ar), 7.44-7.39 (1H, m, Ar), 7.27 
(1H,s, Ar), 7.07-6.93 (2H,m, Ar), 4.76 (2H, d, J = 1.9, 2CH), 4.23 (5H,s, Cp), 4.15 (2H, 
d, J = 1.9, 2CH ), 4.09-3.92 (2H, m, CH2), 1.96-1.91 (2H, m, CH2), 1.48-1.42 (4H, m, 
2CH2), 0.97 (3H, t, J = 7.1, CH3). 
 
13C NMR (CDCl3, 126 MHz): δ = 169.5, 165.2, 159.1, 156.0, 139.8, 131.8, 127.7, 120.6, 
112.2, 110.0, 102.8, 69.4, 68.7, 64.9, 61.7, 28.8, 28.2, 22.4, 14.0.  
 
HRMS-ESI(m/z): found  481.1184 , calcd. for [ C25H26FeN2O3 + Na]
+  481.1185.  
 
Anal. Calcd (%) for C25H26FeN2O3: C, 65.51; H, 5.72; N, 6.11.   
Found (%): C, 65.41; H, 5.80; N, 6.12.  
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5-(4-(Pentyloxy)phenyl)-N-ferrocenylisoxazole-3-carboxamide, 86.                         
The title compound was prepared by a coupling reaction. 5-(4-
(Pentyloxy)phenyl)isoxazole-3-carboxylic acid (27.5 mg, 0.1 mmol) was reacted with 
HOBt (6.8 mg, 0.05 mmol) , HBTU (57 mg, 0.15 mmol) and DIPEA (0.035 mL). in 
CH2Cl2 (2 mL). The reaction mixture was stirred at RT for 45 min. and then added 
aminoferrocene (24.1 mg, 0.12 mmol) stirred for 24 hr. Workup was as above. The orange 
band was eluted with a hexane: ethyl acetate (1:1) mixture, which was collected and 
evaporated to dryness. The yield was 35 mg, 72% (orange solid). 
 
1H NMR (CDCl3, 500 MHz): δ = 7.94 (1H, s, Ar), 7.75-7.70 (2H, m, Ar), 7.27 (2H, s, 
Ar), 7.00-6.93 (2H, m, 2CH2 ), 6.89 (1H,s, Ar), 4.75-4.71 (2H, m, 2CH), 4.22 (5H, s, Cp), 
4.06-4.01 (2H, m, 2CH) 1.83-1.76 (2H, m, CH2), 1.45-1.42 (4H, m, 2CH2), 0.96 (3H, s, 
CH3).  
 
13C NMR (CDCl3, 126 MHz): δ = 172.0, 161.2, 159.1, 156.9, 127.6, 119.2, 115.1, 97.5, 
93.2, 69.3, 68.3, 64.9, 61.7, 28.8, 28.1, 22.4, 14.0.  
 
HRMS-ESI(m/z): found 459.1333 , calc. for [ C25H26FeN2O3 + H]
+ 459.1366.  
 
Anal. Calcd (%) for C25H26FeN2O3: C, 65.51; H, 5.72; N, 6.11.  
Found (%): C, 65.51; H, 5.82; N, 6.18.  
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1-Cyclohexyl-N-ferrocenyl-N-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide, 
87. 
The title compound was prepared by reacting 1-cyclohexyl-N-ferrocenyl-4-oxo-1,4-
dihydroquinoline-3-carboxamide (110 mg, 0.2 mmol) with NaH (10 mg, 0.4 mmol) in 
dry DMF (5 mL). The reaction mixture was stirred at RT for 20 min, and then 
iodomethane (45 μL, 0.7 mmol) was added. After stirring at RT overnight the mixture 
was extracted with EtOAc, then washed with brine and H2O, dried over MgSO4, and 
evaporated. A yellow band was eluted, using chromatography, with a hexane/ethyl acetate 
(2:3) mixture, collected, and evaporated to dryness. The yield was 38 mg, 41% (yellow 
solid). Crystallization by diffusion between CH2Cl2 and hexane provided yellow crystals.  
 
HRMS-ESI(m/z): found 469.1576, calcd for [C27H28FeN2O2 + H]
+ 469.1573.  
 
Anal. Calcd (%) for C27H28FeN2O2: C, 69.24; H, 6.03; N, 5.98.  
Found (%): C, 69.19; H, 6.10; N, 6.03.  
 
LCMS purity (UV) = 100%, tR 18.20 min. LCMS purity (positive ion, TIC) = 91.6%, tR 
18.27 min. 
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Competition Binding Assay.  
 
Stock solutions of the compounds were prepared in DMSO and further diluted 
with the binding buffer to the desired concentration. Briefly, [3H]-CP-55,940 (0.5 nM), 
nonselective human CB1 and CB2 cannabinoid receptor, were added to 6 μg of membranes 
from CB1- or CB2-overexpressing CHO cells in binding buffer (50 mM Tris-HCl, 5 mM 
MgCl2, 2.5 mM EDTA, 0.5 mg/mL BSA, pH 7.4). After 90 min at 30 °C, the incubation 
was stopped and the solutions were rapidly filtered over a UniFilter-96 GF/C glass fiber 
plate, presoaked in PEI (0.05%) on a Filtermate UniFilter 96-Harvester (PerkinElmer), 
and washed 10 times with ice-cold 50 mM Tris-HCl pH 7.4. The radioactivity on the 
filters was measured using a TopCount NXT microplate scintillation counter 
(PerkinElmer) using 30 μL of MicroScint 40 (PerkinElmer). Assays were performed at 
least in triplicate in three independent experiments. The nonspecific binding was 
determined in the presence of 5 μM (R)-(+)-WIN 55,212-2 (Sigma). 
 
Cell-Based HTRF cAMP Assay.  
 
Cellular cAMP levels were measured using reagents supplied by Cisbio 
International (HTRF dynamic 2 cAMP kit). Briefly, CHO-CB2 cells were harvested and 
were collected by centrifugation for 5 min at 1200 rpm. The cells were then resuspended 
in an appropriate final volume of culture medium and incubated with the 
phosphodiesterase inhibitor IBMX (0.5 mM). Cells were incubated for 15 min with the 
compounds at room temperature in a 384-well plate (2000 cells per well) before the 
addition of forskolin (3 μM) for 30 min at room temperature. The dye d2-conjugated 
cAMP and Europium cryptate-conjugated anti-cAMP antibodies were added to the assay 
plate, according to the manufacturer’s instructions. After 1 h incubation at room 
temperature, the plate was read on a Spectramax microplate reader (Molecular Devices) 
with excitation wavelength at 340 nm and emission wavelengths at 665 and 620 nm. 
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Cell Culture and Proliferation Assay.  
 
CHO-WT, CHO-CB2, and HT29 cells were grown at 37 °C in a humidified 
atmosphere containing 5% CO2, in DMEM-GlutaMAX medium (Life Technologies) 
supplemented with 10% fetal bovine serum, penicillin (100 IU/mL), and streptomycin 
(100 μg/mL). In the cell proliferation assay, cells were plated in triplicate on 96-well 
plates (3 × 103 cells per well) and incubated for 24 h. Cells were then incubated in culture 
medium that contained 10 μM test compounds. After 72 h, cell growth was estimated by 
the colorimetric MTS test. 
 
X-ray Crystallography.  
 
Single-crystal X-ray diffraction analyses were performed using a Rigaku FRE+ 
equipped with either VHF (78,80) or HF Varimax confocal mirrors (79, 87), an AFC10 
goniometer, and an HG Saturn 724+ detector equipped with an Oxford Cryosystems low-
temperature apparatus operating at T = 100(2) K.61 CrystalClear-SM Expert 3.1 b27 was 
used to record images, process data, and apply empirical absorption corrections, and unit 
cell parameters were refined against all data. The structures were solved by charge 
flipping using SUPERFLIP and refined on Fo
2 by full-matrix least-squares refinements 
using SHELXL-201262 as implemented within OLEX2. All non-hydrogen atoms were 
refined with anisotropic displacement parameters. Hydrogen atoms were added at 
calculated positions except those attached to heteroatoms, which were located from the 
difference map and restrained to a reasonable geometry. All hydrogen atoms were refined 
using a riding model with isotropic displacement parameters based on the equivalent 
isotropic displacement parameter (Ueq) of the parent atom. Figures were produced using 
OLEX2iv. The CIF files for the crystal structures of 78-80 and 87 have been deposited 
with the CCDC and have been given the deposition numbers 1479553−1479556, 
respectively.4 Those for 84, 85 will be deposited once we publish this work. 
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Chapter 3 
 
Synthesis of HDAC inhibitors containing 
     a ferrocene unit. 
 
3.1 Overview 
Benzamide compounds containing ferrocene have been synthesized and their 
application as HDAC inhibitors has been studied. The products were characterized by 
elemental analyses, NMR spectroscopy, mass spectrometry, LC-MS, IR spectroscopy and 
some were further analysed by X-ray crystallographic studies. One of them, N1-(2-
aminophenyl)-N8-ferrocenyloctanediamide, (Pojamide) 111 displayed nanomolar 
potency vs. HDAC3 compared to RGFP966, a potent and selective HDAC3 inhibitor. 
Pojamide had better activity in HCT116 colorectal cancer cell invasion assays; however, 
TCH106 and Romidepsin, potent HDAC1 inhibitors, are more effective than Pojamide 
in cellular proliferation and colony formation assays. These latter’s data propose that 
HDAC 1 & 3 polypharmacology (acting on multiple targets) is amenable to achieving 
maximum anti-cancer advantages. Pojamide has also been investigated in redox-
pharmacology and its activity rationalised by molecular modelling. Indeed, treating 
HCT116 cells (Human colon carcinoma) with Pojamide and SNP (sodium nitroprusside) 
led to greatly enhanced cytotoxicity and DNA damage attributed to activation to an Fe(III) 
species.  
3.2 Introduction 
Histone deacetylases (HDACs) are a class of enzymes which remove acetyl groups 
(H3C-C=O) from histones, which are proteins that DNA wraps around in the nucleus.  
HDACs have been classified into three classical HDAC classes which contain 11 HDACs 
according to their subcellular location, homology to yeast proteins, and enzymatic 
activities, there are Class I (HDAC 1, 2, 3, 8), Class IIa (HDAC 4, 5, 7, 9), Class IIb 
(HDAC6, 10) and Class IV (HDAC11) as well as sirtuins.1 HDACs are promising 
therapeutic targets for cancer treatment.  HDAC inhibitors (HDACis) are a class of 
therapeutics with potential as anticancer drugs and can be classified into several groups 
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by their functional groups that can bind to the zinc ion of the HDAC such as hydroxamic 
acids (or hydroxamates), thiols, benzamides, electrophilic ketones and aliphatic acid 
compounds.2  Their pharmacophore contains a cap-linker-ZBG (zinc binding group) 
(Figure 3.2). Well known HDACis include suberoylanilide hydroxamic acid (SAHA or 
Vorinastat) and Romidepsin3 which are clinically useful anticancer agents that have 
received Food and Drug Administration approval for treating patients with cutaneous T-
cell lymphoma.4-5 Selective inhibitors of HDAC3 such as TCH106 and RGFP9666 
usually contain a benzamide (or ortho-anilide) ZBG and are found in CNS applications2 
and cancer.7 Recent studies using HDAC3-overexpressing HCT116 cells showed that 
silencing individual HDACs (1-3) through RNA interference (RNAi) is insufficient to 
achieve similar levels of growth arrest and apoptosis induced by unselective HDACis e.g. 
Trichostatin A8 (Figure 3.2).  
 
 
 
 
 
 
 
 
Figure 3.1. Romidepsin and Trichostatin A. 
 
 
 
 
 
 
 
 
 
Figure 3.2. Hydroxamic acid based SAHA, JAHA and known selective benzamide HDAC3is. 
 
 
Romidepsin Trichostatin A 
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3.2.1 Mechanism of HATs and HDACs 
The acetylation and deacetylation of histones play an important role in eukaryotic 
cells (mammalian cells, that contain a nucleus and other organelles with membranes).9 
The acetylation status is defined by histone deacetylases (HDACs) and histone acetyl-
transferases (HATs) where HDACs remove the acetyl groups and HATs add the acetyl 
groups.10 Chromosomes are a genetic material of the cells and are made up from 
chromatin, which contains histone protein/non-histone protein (positively charged) and 
deoxyribonucleic acid (DNA, negatively charged). Within the chromatin, the repeating 
units are called nucleosomes, which are made up from DNA wrapped around the core of 
8 histones (histone octamer is two copies of H2A, H2B, H3 and H4 in compact form). 
Acetylation of histones by HAT will loosen the wrapping of DNA to histones (open 
chromatin structure), then gene expression will be allowed and the opposite direction is 
deacetylation of histones by HDACs, which will tighten DNA around the histone core 
(condensed chromatin structure) (Figure 3.3).  The overexpression of HDAC can lead to 
cancer, hence a solution of this problem is to design HDAC inhibitors for blocking HDAC 
enzymes.  
 
 
 
Figure 3.3. Acetylation and deacetylation of histones. 
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 The binding mode of SAHA in HDAC3 (PDB code: 1T69) is shown in Figure 
3.4.11  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Cocrystal structure of SAHA in HDAC8. 
 
The role of zinc in HDACs (Scheme 3.1) is to activate water, which attacks an acetyl 
group leading to a deacetylated lysine. Designing an inhibitor to bind to zinc will block 
this deacetylation and leave an acetylated lysine. 
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Transition metal-based anticancer agents are increasing rapidly because of the 
ability of a metal atom to help solve protein  x-ray crystal structures, undergo redox and 
ligand exchange reactions and the variety  of coordination numbers to provide different 
geometries and oxidation states that cannot be achieved with organic therapeutics.12-13 
Many metal complexes have been synthesized and their applications have been studied 
such as platinum, ruthenium, rhodium, iridium, iron and so on.14 Polyoxometalate-based 
HDAC inhibitors have also been synthesized and studied.15 
 
  A novel anti-cancer platinum complex, cis-[PtII(NH3)2(malSAHAH-2)], 90 has 
been published as a bifunctional drug candidate (DNA binding, (PtII) and HDACi, 
(malSAHA)) and the results showed that the cytotoxicity of 90 (IC50 9 ± 3 µM) is 
comparable to cisplatin (IC50 2.9 ± 0.1 µM) against ovarian cancer cell lines A2780P and 
they found the presence of the HDACi, malSAHA (89) in 90, is thus enhancing its 
cytotoxicity.16    
 
 
Figure 3.5. malSAHA 89, Pt(II) complex 90 and cisplatin. 
 
 RuII, 91 and RhIII, 92 complexes have been synthesized and their applications as 
HDAC inhibitors have been studied, which provided antiproliferative activity against 
H460 non-small cell lung carcinoma cells that is comparable to the clinically used HDAC 
inhibitor suberoylanilide hydroxamic acid (SAHA).17 
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Figure 3.6. Ru(II) 91, Rh(III) 92 complexes and SAHA. 
 
 A series of fluorescent ruthenium(II) complexes (94, 95 and 96) have also been 
synthesized as potent anticancer agents containing N1-hydroxy-N8-(1,10-phenanthrolin-
5-yl)octanediamide, 93. The results showed the most effective compound is 96, which 
provided almost the same activity to that of SAHA and 96 is highly active against a panel 
of human cancer cell lines and shows lower toxicity to normal cells (Figure 3.7).18  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Fluorescent ruthenium(II) complexes 94, 95 and 96. 
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A series of cyclometalated Ir(III) complexes as HDACis and photodynamic 
therapeutic agents have been studied. Compounds 97, 98, 99 and 100 showed potent 
cytotoxicity towards the cancer cell lines screened and show much lower phototoxicity 
against human normal cells. 97 induces apoptotic cell death and under UV light 
irradiation, the biological effects of 97 are significantly enhanced (Figure 3.8).19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Cyclometalated Ir(III) complexes 97, 98, 99 and 100. 
 
Earlier work from Spencer and co-workers described N8-ferrocenyl-N1-hydroxy-
octanediamine (JAHA; “Jay Amin Hydroxamic Acid”), an analogue of SAHA, 
containing a ferrocenyl group as a phenyl bioisostere. JAHA analogues 35 displayed 
anticancer activity and inhibition of several HDACs.20 “Click JAHAs” 36 also had good 
HDAC inhibition, (Figure 3.9).21  
 
Figure 3.9. SAHA, JAHA 35 and click JAHAs 36.  
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Gasser’s group has shown the synthesis of light activated organometallic HDAC 
inhibitors, p-Fc-SAHA (41), that release a JAHA-type HDAC inhibitor,22 as shown in the 
cleavable linker (Figure 3.10). 
 
 
 
 
 
 
 
Figure 3.10. Light activatable organometallic HDAC inhibitor, p-Fc-SAHA.  
 
 A hydroxamic acid compound has been synthesized by replaced the phenyl ring 
in SAHA with a [Re(CO)3(Cp)] bioisostere (Figure 3.11) and its cytotoxicity is in the 
same range as SAHA.23   
 
 
 
 
 
Figure 3.11. Re-HDACi 101.  
 
 A gold (III) complex has been synthesized and its cytotoxicity was studied in a 
panel of human breast cancer cell lines, which was 100-fold to 3,000-fold higher than that 
of cisplatin (Figure 3.12).24 
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Figure 3.12. Au-HDACi 102. 
 
Hence, metal based HDACis show much promise in cancer therapy. Our studies on the 
design of a HDAC3i are now described. 
 
3.3 Results and Discussion 
We wished to extend our JAHA chemistry to ortho-anilide (benzamide) analogues, 
hoping that this may lead to HDAC3-specificity and lower toxicity issues documented 
for hydroxamate ZBGs; for example, a Lossen rearrangement will transform an activated 
hydroxamate into isocyanate and lead to the known toxicity of hydroxamic acids (Scheme 
3.2).25  
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Scheme 3.2. Lossen rearrangement of hydroxamate. 
 
The synthesis of the benzamides 110 and 111 (Pojamide) is shown in Scheme 3.3.  Hence, 
the amide coupling of ferrocenyl amine with an acid chloride led to the amides 104 and 
105. Hydrolysis of the terminal ester groups led to the carboxylic acids 106 and 107 which 
were coupled to give the Boc-protected benzamides 108 and 109. Acid deprotection gave 
the final benzamides 110 and 111. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.3. Synthesis of 110 and Pojamide, 111. 
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Compounds 108 and 109 were characterised in the solid state by X-ray 
crystallography (Figure 3.13).26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13. X-ray structures of 108 and 109. 
 
 
 
 
 
 
108 
109 
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We confirmed Pojamide’s HDAC3-specificity on a panel of HDACs vs. 110, 
SAHA and known HDAC3is (Table 3.1). Also both 110 and Pojamide displayed ca. 14- 
and 20-fold selectivity respectively towards HDAC3 over HDACs 1/2 and significantly 
greater selectivity over HDACs 4-8. Indeed, Pojamide showed an impressive IC50 of 82 
nM vs HDAC3. Pojamide’s profile was similar to TCH106, but it was less active than 
RGFP966 in its HDAC3-selectivity. Only SAHA displayed activity vs. HDAC8. 
 
 
Table 3.1.  
Biochemical evaluation vs HDAC isoforms 1 – 8. 
 
 
 
 
 
 
 
IC50(M) 
HDAC SAHA[a] 110 Poj[a] RGFP966 TCH106[b] 
1 0.005 8.94 1.19 0.611 0.389 
2 0.015 13.79 1.64 0.576 1.262 
3 0.009 0.606 0.082 0.015 0.049     
4 11.23 >30 >30 >30 >30     
5 9.82 >30 >30 >30 >30     
6 0.02 >30 >30 >30 >30     
7 >30 >30 >30 >30 >30     
8 0.472 >30 >30 >30 >30 
[a] Profiling done in duplicate, n=8. All others n=4; [b] Slow, tight-binding inhibitor, with inverted 
IC50 and Ki values, causes IC50 value to drop over longer pre-incubation periods.29  
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3.3.1 Modelling. (Contributed with help by Rhiannon Jones) 
 
To explore the binding modes of 110 and 111 (Pojamide) in HDAC3 we 
performed docking studies using the recently published structure of HDAC3.27 Docking 
was performed using molecular mechanics GLIDE 6.5 in Schrodinger Suite 2014-4.28 
The docking protocol uses molecular mechanics to predict the strength of non-covalent 
interactions and provides a scoring function. This was used to consider possible binding 
modes and the associated conformational changes within receptor active sites. We found 
that Pojamide bound the zinc active-site forming hydrogen bonds between the N-H of the 
amide and the carbonyl of Asp93, the (ortho-anilide) benzamide amide N-H and the 
carbonyl of Gly143, the aniline NH2 and the nitrogen of His134 and the carbonyl of 
Asp170 as well as the characteristic benzamide-zinc interaction. 110 is docked slightly 
shifted from Pojamide. It forms hydrogen bonds with Asp93 and Gly143. However, the 
substitution of the 6-carbon aliphatic chain for a 4-carbon chain results in a rotation of 
the benzamide group leading to a loss of key interactions, namely, hydrogen bonding with 
His134 and Asp170 as well as forcing zinc coordination from the benzamide aniline to 
the amide carbonyl. Docking poses of 111(Pojamide) and 110 in HDAC3 (PDB code: 
4A69). Top docking poses of 111 (slate, A) and 110 (teal, B) in HDAC3. C) Superposition 
of the active site of HDAC3 (grey) and HDAC86,29 (PDB code: 1T69, green) showing 
key residues overlaid with 111 top docking pose in HDAC3. Colour Scheme: Hydrogen 
bonds shown in black dashed lines, π-π interactions shown in green dashed lines. 
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Figure 3.14. Docking poses of 111 (Pojamide) and 110 in HDAC3. 
 
3.4 Biological Results (contributed by Dr Cory A. Ocasio) 
We attempted to explore the inhibitory activity of the benzamides in HDAC3 
overexpressing cervical and colorectal cancer cell lines. HeLa, HT-29 and HCT116 cells 
are tumour forming cell lines that have been used previously as model systems to 
characterise HDACis.8,30 We confirmed in this study the malignant cancer cell lines 
HeLa, HT-29 and HCT116 had high HDAC3 expression levels (Figure 3.15A). However, 
immortalised Retinal Pigment Epithelium (RPE) cells, which do not form tumours and 
have a longer lifespan, and cannot form tumours, had low HDAC3 levels. 
 
Based on these data, this small panel of cell lines was treated with increasing 
concentrations of 110, 111 (Pojamide) and the control HDAC3i RGFP966 and TCH106. 
RGFP966 shows a 5.5-fold greater potency than Pojamide in blocking HDAC3 activity 
(Table 3.1), yet it was found that RGFP966 and Pojamide are comparable at inhibiting 
HCT116 cellular proliferation, displaying GC50 values of 8.9 and 8.6 μM respectively 
(Figure 3.15B). RPE cells were as sensitive to Pojamide as HCT116 cells, but were not 
inhibited by RGFP966. TCH106 displayed superior potency against all cell lines with 
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GC50 values ranging from 1 – 2 µM and completely blocked colony formation at 10 µM 
in HCT116 colony formation assays compared to 75 and 60% inhibition of colony 
formation by Pojamide and RGFP966 respectively (Figures 3.15B-F). Interestingly, 
TCH106 is 1.5- and 3-fold more potent toward HDAC1 inhibition over RGFP966 and 
Pojamide respectively and proliferating RPE cells have been shown to overexpress 
HDACs 1, 2 and 5,31 suggesting that HDAC1 inhibition is in part responsible for the anti-
proliferative effects of Pojamide and TCH106 in these cell lines. In fact, cellular 
proliferation and colony formation assays using Romidepsin, a very potent and selective 
HDAC1/2 inhibitor (reported IC50 values of 36 and 47 nM respectively),
32 revealed a 
GC50 value of 0.52 ± 0.02 nM and near complete inhibition of colony formation at 0.5 
nM; clearly the most potent anti-proliferative HDACi tested in this study. HeLa and HT-
29 cells were only mildly inhibited by Pojamide and RGFP966 showing maximal growth 
inhibition of ~40 and 30% at 10 μM respectively, and in all cases compound 110 was 
ineffective at inhibiting cellular proliferation.  
 
Next, to establish the anti-invasive properties of Pojamide against known HDACis, we 
investigated the effects of RGFP966, TCH106 and Pojamide on HCT116 cellular 
invasion. In this assay, we decided to test compounds at 1x and 0.1x of their GC50 value 
determined using the HCT116 cellular proliferation assay. At the lowest concentrations 
tested, only Pojamide demonstrated robust inhibition of invasion, with about 70% 
inhibitory activity; however, at the 1x concentrations both RGFP966 and Pojamide, 
exhibiting ca. 40 and 15-fold selectivity for HDAC3 inhibition compared to HDAC1, 
inhibited invasion by about 90% compared to 70% for TCH106, which showed only 7-
fold selectivity for HDAC3 vs. HDAC1 inhibition (Figures 3.15H-J).  
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Figure 3.15. A) Western blot analysis of HDAC3 and α-Tubulin in Retinal Pigment Epithelium 
(RPE) cells and HeLa, HT-29 and HCT116 cells. B-E) HCT116 (B), RPE (C), HeLa (D) and HT-
29 (E) CellTiter-Blue proliferation assays. F) HCT116 colony formation assays; % Colony 
formation (normalised to DMSO control) was quantitated manually and the average ± S.D. was 
plotted. G) Inhibitory activity of Romidepsin on HCT116 cellular proliferation. H-J) HCT116 
cellular invasion assays in the presence of RGFP966 (H), TCH106 (I) and Pojamide (J). 
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Pojamide appears more efficacious in preventing HCT116 cellular invasion, 
particularly at lower concentrations (i.e. 1 µM). In addition, we wanted to look to oxidise 
the iron atom in the ferrocene unit to offer a unique advantage at targeting cancer cells. 
In Ehrlich ascites tumour (EAT) cells and HPB (human leukemic T lymphocytes) it was 
shown that treatment with ferrocenium salts (e.g. Fe(III)Cp2PF6) inhibited tumour 
growth, whereas their ferrocene (II) derivatives were inactive. Indeed, ferrocenium’s 
toxicity involves the generation of OH  radicals and the rapid induction of DNA-
damage.33 Pojamide was also studied by cyclic voltammetry and its voltammograph is 
shown in Figure 3.17 (contributed with help by Nikolaos Tsoureas). It shows a reversible 
process at 0.39V vs Fc*+/0 (Fc = Ferrocene, Fc* = Fe(Cp*)2), which is attributed to the 
reversible oxidation of the ferrocenyl moiety. We used Fc* as the internal reference 
standard as attempts to use Fc hampered proper referencing of the observed process. 
Nevertheless, given that the Fc* redox couple is found -0.59V vs. ferrocene (Fc),8 one 
can extrapolate an approximate value of the depicted in Figure 3.16 ; an observed process 
of -0.20V vs Fc. CV scans with different scan rates were also recorded (200, 100, 150, 50 
mV.s-1) with no observed change in the reversibility of the process or the ia/ic ratio. Given 
the observed value for the oxidation of Pojamide and calculating approximately its value 
at 280 mV vs. the Ag/AgCl.KCl(sat.) reference electrode, we find that the neutral Pojamide 
undergoes facile oxidation by SNP ([Fe(II)(CN)5NO]/[Fe(III)(CN)5NO] 760 mV vs.  
Ag/AgCl.KCl(sat.)). 
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Figure 3.16. Overlaid CV scans (6) of Pojamide in DMSO (0.05M [N(n-Bu)4]PF6  electrolyte) in 
the anodic direction. Scan rate: 300 mV.s-1; ia/ic  = 1 (Working electrode: Glassy C; Reference 
Electrode: Ag; Counter Electrode: Pt). The voltamogram was referenced by adding a CH2Cl2 
solution (ca. 0.5 ml) of Fc* (1-2 crystals) in the DMSO analyte solution, resulting in no change 
in the characteristics of the observed voltamogram. 
 
 In order to take advantage of ferrocenium cytotoxicity, we generated the 
ferrocenium species 113 (Fe(III)-Poj) by reacting Pojamide with nitrosonium (NO+) 
tetrafluoroborate and this was confirmed by cyclic voltammetry34 (Scheme 3.3). Hence, 
we hypothesised that intracellular generation of NO+ in the presence of Pojamide might 
also lead to Fe(III)-Poj in cells. 
 
Scheme 3.3. Synthetic ferrocenium Pojamides. 
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It has previously been reported that sodium nitroprusside (SNP) leads to 
intracellular NO+ release,35 and neuronal PC12 cells have shown that SNP alone triggers 
apoptosis at very high concentrations > 30 µM.36 To develop a cell-based assay utilising 
SNP as an NO+ donor, we conducted cytotoxicity studies using the colony formation 
assay. At 25 µM SNP, HCT116 colony formation is reduced by about 30%; however, 
addition of 500 µM GSH completely eliminated SNP cytotoxicity. GSH is a free radical 
scavenger and its cytoprotective effects were demonstrated in our assay at concentrations 
of 50 and 500 µM, whereby GSH treatments enhanced colony formation by about 4 and 
10% respectively. Reacting with GSH to form innocuous NO may further reduce SNP 
cytotoxicity.36 After identifying the optimal conditions for SNP/GSH treatment, we 
treated HCT116 cells with increasing concentrations of inhibitor in the presence and 
absence of SNP/GSH. The generation of Fe(III)-Poj was monitored by blotting for the 
DNA-damage marker phospho-H2AX (pH2AX) (Figure 3.17A-D). Without SNP/GSH, 
increasing concentrations of RGFP966 and Pojamide reduced pH2AX levels, but 
addition of SNP/GSH to cells treated with Pojamide led to an initial decrease in pH2AX, 
with appearance of the DNA-damage marker at concentrations greater than 2 µM (Figure 
3.17A-D). In a longer time-course (6-d) with 4 µM inhibitor (± SNP/GSH), only the 
Pojamide/SNP/GSH combination led to significant DNA-damage in comparison to the 
DNA-damage caused by cisplatin (4 µM) (Figure 3.17E). 
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Figure 3.17. A-C) Western analysis of pH2AX and α-tubulin (Tub) in HCT116 cells treated for 
3-d with (A) RGFP966, (B) Poj and (C) Poj + SNP/GSH. D) The pH2AX/Tub ratio was 
determined via densitometry and the average ratio normalised to DMSO control was plotted as 
the mean ± S.D. E) Western analysis of pH2AX and α-tubulin (Tub) in HCT116 cells treated for 
6-d as indicated above. F) NAD+ and total NAD+/NADH levels normalised to the DMSO 
control; the average (n=10) was plotted ± S.D. G,H) HCT116 colony formation assays; % Colony 
formation (H) (normalised to DMSO control) was quantitated manually and the average ± S.D. 
was plotted. The t-test statistical module of Prism 6.0 was used to determine p-values (ns (not 
statistically significant): P > 0.05; *: P ≤ 0.05; **: P ≤ 0.01; ***: P ≤ 0.001). 
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To further support that our SNP/GSH treatment in the presence of Pojamide leads to 
production of Fe(III)-Poj, we assessed the levels of NAD+ in cells using the 
NAD/NADH-Glo Assay since the one one-electron transfer from NADH to ferrocenium 
oxidants such as Fe(III)Cp2PF6 shows that ferrocenium salts can successfully oxidise 
NADH to NAD+ in vitro.37 To show this in cells, we treated HCT116 cells with 
DMSO/SNP/GSH and 2.5 µM Pojamide with and without SNP/GSH. For each condition, 
total NAD+/NADH levels remained the same, but Pojamide in the presence of SNP/GSH 
led to an increase in NAD+ levels; similar to those obtained with synthetic Fe(III)-Poj. In 
contrast, Pojamide treatment alone decreased NAD+ levels (Figure 3.18F). With cellular 
validation of Fe(III)-Poj generation, we tested our system in the HCT116 colony 
formation assay (Figures 3.18G,H). Pojamide alone caused a significant decrease in 
colony formation, which was enhanced by the addition of SNP/GSH; 27 and 53% 
inhibition respectively. At 4 µM, RGFP966, with and without SNP/GSH, displayed a 10 
– 15% reduction in colony formation; however, like Pojamide, both ferrocenium salts 
were less effective without SNP/GSH. In combination with SNP/GSH, Fe(III)-Poj and 
Fe(III)Cp2PF6 caused a slight, about 10%, reduction in colony formation (Figure 
3.18G,H). Interestingly, colonies resulting from treatment with ferrocenium salts and 
SNP/GSH were larger, but overall fewer colonies formed; a result similar to RGFP966 
treatment. Although the cytotoxicity of ferrocenium salts is well documented, their 
activity is ~100-fold reduced compared to Pojamide,38 perhaps due to limited membrane 
permeability, and explains their weak inhibition at the 4 and 20 µM concentrations tested. 
 
3.5 Conclusion 
In summary, the SNP/GSH combination treatment is an ideal system for 
increasing the intracellular ferrocenium concentration from a Pojamide precursor. Also, 
when Fe(III)-Poj is reduced back to the Fe(II) species, it would be available to act upon 
HDACs. In this way, Pojamide is advantageous compared to other similarly potent 
HDACis: it is doubly toxic to cancer cells due to its facile conversion to the cytotoxic 
Fe(III) species in cells, whilst the reduced species inhibits cellular invasion through 
potently targeting HDAC3 and proliferation, to a lesser extent, due to its low micromolar 
HDAC1 inhibitory activity (Scheme 3.4). 
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Scheme 3.4. Model for the enhanced redox-triggered cytotoxicity of Pojamide. 
 
 Lastly, co-treatments of intravenous SNP injection along with Pojamide 
administration might have application when used with pharmacologically distinct 
Fe(II)Cp2-containing drugs (e.g. ferrocifens, hypoxia-induced prodrugs such as the 
prodrug of 114 (Schemes 3.5, 3.6)).39-40  
 
 
Scheme 3.5. The activation process of ferrocifen. 
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Scheme 3.6. Other Fe(II)Cp2 – containing drugs and their activation process. 
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3.6  Experimental 
Solvents and reagents were purchased from commercial suppliers and were used 
without purification. Ferrrocenylamine was purchased from TCI, UK, and used as such. 
All reactions were performed in a fume hood. NMR spectra were recorded on Varian 500 
MHz or 400 MHz spectrometers and chemical shifts are reported in ppm, usually 
referenced to TMS as an internal standard. LCMS was performed using a Shimadzu 
LCMS-2020 equipped with a Gemini® 5µm C18 110Å column and percentage purities 
were ran over 30 minutes in water/acetonitrile with 0.1% formic acid (5 min at 5%, 5%-
95% over 20 min, 5 min at 95%) with the UV detector at 254 nm. High-resolution mass 
spectrometry (HRMS) was performed by the EPSRC National Mass Spectrometry 
Facility, University of Swansea. Elemental analyses were conducted by Stephen Boyer 
(London Metropolitan University). FT-IR spectra were recorded on a PerkinElmer 
Spectrum Version 10.03.06.  
 
 
 
 
N-Boc-o-phenylenediamine, 103.  
The title compound was prepared by using o-phenylenediamine (1.18 g, 10.95 mmol) in 
anhydrous dioxane (12 mL) and added 1M sodium hydroxide (5.90 mL), followed by 
tert-butyldicarbonate (1.1 equiv., 12.05 mmol) as a solution in dioxane (6 mL). The 
reaction mixture was stirred at room temperature overnight (18-h). Extraction was 
performed with dichloromethane. The organic layer was washed with brine, dried 
(MgSO4) and then purification by column chromatography (ethyl acetate : hexane, 7:3) 
yielded a beige solid (1.371 g, 60%). 
 
1H NMR (DMSO-d6, 500 MHz):  = 8.23 (1H, s, NH), 7.17 (1H, d, J=8.0 Hz, CH), 6.84-
6.81 (1H, m, CH), 6.67 (1H, d, J=8.0 Hz, CH), 6.53-6.50 (1H, m, CH ), 4.79 (2H, s, NH2), 
1.45 (9H, s, 3CH3).  
 
13C NMR (DMSO-d6, 126 MHz).  = 154.1, 141.7, 125.4, 125.0, 124.2, 116.7, 116.2, 
79.1, 28.7. 
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Methyl-6-oxo-6-(ferrocenylamino)hexanoate, 104.20  
The title compound was prepared by using a microwave tube equipped with a magnetic 
stirrer and ferrocenylamine (0.3g, 1.5 mmol, 1 equiv.), methyl-6-chloro-6-oxohexanoate 
(0.30 mL, 1.94 mmol, 1.3 equiv, d=1.144) and anhydrous THF (5 mL). Dry triethylamine 
(0.83 mL, 6.00 mmol, 4 equiv., d=0.73) was added dropwise at rt.  The reaction mixture 
was placed in a (CEM Explorer) microwave and the temperature was ramped to 150 oC 
with an initial power of 150 W for 10 mins. The cooled crude reaction mixture was diluted 
with distilled water (20 mL), extracted with ethyl acetate (20 mL). The organic layer was 
washed with brine (2 x 10 mL, sat.).  The separated organic layer was dried using 
magnesium sulphate, filtered through a cotton wool plug. The dry organic extract was 
concentrated under reduced pressure and then purified by column chromatography 
(hexane : EtOAc = 1:1) to give an orange solid (0.369g, 72% yield).  
 
1H NMR (DMSO-d6, 500 MHz):  = 9.20 (1H, s, NH), 4.58-4.55 (2H, m, 2CH), 4.08 (5H, 
s, Cp), 3.94-3.90 (2H, m, 2CH), 3.58 (3H, s, CH3), 2.38-2.32 (2H, m, CH2), 2.17-2.14 
(2H, m, CH2), 1.57-1.54 (4H, m, 2CH2).  
 
13C NMR (DMSO-d6, 126 MHz):  = 173.6, 170.9, 96.1, 69.2, 64.1, 61.1, 51.6, 39.7, 
36.0, 33.5, 25.2, 24.5. 
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Methyl-8-oxo-8-(ferrocenylamino)octanoate, 105.20  
To a microwave tube equipped with a magnetic stirrer was added ferrocenylamine (0.3 g, 
1.5 mmol, 1 equiv.), methyl-8-chloro-8-oxooctanoate (0.28 mL, 1.94 mmol, 1.3 equiv, 
d=1.156) and anhydrous THF (5 mL). Reagent grade triethylamine (0.83 mL, 6.00 mmol, 
4 equiv., d=0.73) was added drop wise at room temperature.  The reaction mixture was 
placed in a CEM Explorer microwave and the temperature was ramped to 150 oC at an 
initial power of 150 W for 10 mins. The cooled crude reaction mixture was diluted first 
with distilled water (20 mL), then extracted with ethyl acetate (20 mL) and the organic 
layer was washed with brine (2 x 10 mL, sat.).  The separated organic layer was dried 
using magnesium sulphate and then filtered through a cotton wool plug.  The dry organic 
extract was concentrated under reduced pressure and then purified by column 
chromatography (hexane : EtOAc = 1:1) to give an orange solid (0.360g, 65% yield). 
 
1H NMR (DMSO-d6, 500 MHz):  = 9.17 (1H, s, NH), 4.58-4.55 (2H, m, 2CH), 4.08 (5H, 
s, Cp), 3.93-3.91 (2H, m, 2CH), 3.57 (3H, s, CH3), 2.29 (2H, t, J=7.3 Hz, CH2), 2.13 (2H, 
t, J=7.3 Hz, CH2), 1.58-1.52 (4H, m, 2CH2), 1.32-1.28 (4H, m, 2CH2).  
 
13C NMR (DMSO-d6, 126 MHz):  = 173.7, 171.2, 96.2, 69.1, 64.1, 61.0, 51.6, 36.4, 
33.7, 28.7, 28.6, 25.5, 24.8. 
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6-Oxo-6-(ferrocenylamino)hexanoic acid, 106.20  
The methyl ester precursor (344 mg, 1.00 mmol, 1 equiv.) was suspended in THF (10 
mL). To this was added a solution of sodium hydroxide (2 equiv., 80 mg) in water (1 mL). 
The reaction mixture was stirred at room temperature for 4 h. After that, the organic 
volatiles were removed in vacuo, the reaction mixture was diluted with water and 
acidified with conc. HCl to pH ~ 4. A precipitate formed which was filtered under 
vacuum, washed with water and air-dried to give the expected product as an orange solid 
(220 mg, 67%).  
 
1H NMR (DMSO-d6, 500 MHz):  = 11.95 (1H, s, OH), 9.20 (1H, s, NH), 4.57-4.55 
(2H,m, 2CH), 4.08 (5H, s, Cp), 3.95-3.90 (2H, m, 2CH), 2.23 (2H, t, J=6.9 Hz, CH2), 
2.15 (2H, t, J=6.9 Hz, CH2), 1.57-1.50 (4H, m, 2CH2).  
 
13C NMR (DMSO-d6, 126 MHz):  = 174.7, 171.0, 96.1, 69.4, 69.2, 64.1, 61.1, 39.6, 
36.1, 33.9, 25.3, 24.6. 
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8-Oxo-8-(ferrocenylamino)octanoic acid, 107.20  
The methyl ester precursor (371 mg, 1.00 mmol, 1 equiv.) was suspended in THF (10 
mL). A solution of sodium hydroxide (2 equiv., 80 mg) in water (1 mL) was next added. 
The reaction mixture was stirred at room temperature for 4 h, after which, the organic 
volatiles were removed in vacuo. The reaction mixture was diluted with water and 
acidified with conc. HCl to pH ~ 4. A precipitate formed which was filtered under 
vacuum, washed with water and air-dried to give the expected product as an orange solid 
(236 mg, 66%).  
 
1H NMR (DMSO-d6, 500 MHz):  = 11.93 (1H, s, OH), 9.18 (1H, s, NH), 4.56 (2H, s, 
2CH), 4.08 (5H, s, Cp), 3.92 (2H, s, 2CH), 2.20-2.14 (4H, m, 2CH2), 1.58-1.52 (4H, m, 
2CH2), 1.36-1.24 (4H, m, 2CH2). 
 
13C NMR (DMSO-d6, 126 MHz):  = 173.7, 171.2, 96.2, 69.1, 64.1, 61.0, 51.6, 36.4, 
33.7, 28.7, 28.6, 25.5, 24.8. 
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Tert-butyl-2-(6-oxo-6-(phenylamino)hexanamido)ferrocenylcarbamate, 108.41  
6-Oxo-6-(ferrocenylamino)hexanoic acid (493.6 mg, 1.5 mmol, 1 equiv.) and N-Boc-o-
phenylenediamine (343.4 mg, 1.65 mmol, 1.1 equiv.) were dissolved in dichloromethane 
(18 mL). To this triethylamine (1.17 mL, 9 mmol) was added and the mixture was cooled 
in an ice bath. Next, propane phosphonic acid anhydride T3P (50% solution in DMF, 1.38 
mL, 1.1 mmol)2 was added and the reaction mixture was allowed to warm up to room 
temperature overnight. Then the mixture was poured into a saturated solution of K2CO3, 
stirred for 30 min. and extracted into CH2Cl2 (DCM). The organic layer was dried 
(MgSO4), filtered and evaporated in vacuo. The residue was purified by trituration with 
DCM to give an orange solid (576.3 mg, 74%). Crystallization by solvent evaporation of 
DCM provided yellow crystals. 
 
1H NMR (DMSO-d6, 500 MHz):  = 9.44 (1H, s, NH), 9.22 (1H, s, NH), 8.31 (1H, s, 
NH), 7.53 (1H, d, J=7.8 Hz, CH), 7.41 (1H, d, J=7.8 Hz, CH), 7.12-7.04 (1H, m, CH), 
7.06 (1H, d, J=7.8 Hz, CH), 4.57 (2H, s, 2CH), 4.08 (5H, s, Cp), 3.93 (2H, s, 2CH), 2.37 
(2H, d, J=8.3 Hz, CH2), 2.19 (2H, t, J=6.1 Hz, CH2), 1.65-1.56 (4H, m, 2CH2), 1.45 (9H, 
s, 3CH3). 
 
13C NMR (DMSO-d6, 126 MHz):  = 171.0, 153.5, 130.1, 125.4, 125.3, 124.3, 124.1, 
96.1, 79.8, 69.2, 64.1, 61.1, 36.2, 28.7, 28.5, 25.3. 
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Tert-butyl-2-(8-oxo-8-(phenylamino)octanamido)ferrocenylcarbamate, 109.41  
Methyl-8-oxo-8-(ferrocenylamino)octanoic acid (215 mg, 0.6 mmol, 1 equiv.) and N-
Boc-o-phenylenediamine (137.4 mg, 0.66 mmol, 1.1 equiv.) were dissolved in 
dichloromethane (7.7 mL). To this triethylamine (0.5 mL, 3.6 mmol) was added and the 
mixture was cooled in an ice bath. Next, propane phosphonic acid anhydride T3P (50% 
solution in DMF, 0.59 mL, 0.66 mmol) was added and the reaction mixture was allowed 
to warm up to room temperature overnight. Then the mixture was poured into saturated 
solution of K2CO3, stirred for 30 min. and extracted into CH2Cl2. The organic layer was 
dried (MgSO4), filtered and evaporated in vacuo. The residue was purified by trituration 
with DCM to give the orange solid (233.1 mg, 71%). Crystallization by solvent 
evaporation of DCM provided yellow crystals. 
 
1H NMR (DMSO-d6): 9.40 (1H, s, NH), 9.15 (1H, s, NH), 8.26 (1H, s, NH), 7.54-7.48 
(1H, m, CH), 7.42-7.35 (1H, m, CH), 7.13-7.09(1H, m, CH), 7.08-7.03 (1H, m, CH), 4.55 
(2H, s, 2CH), 4.06 (5H, s, Cp), 3.91 (2H, s, 2CH), 2.33 (2H, t, J=7.4 Hz, CH2), 2.14 (2H, 
t, J=7.4 Hz, CH2), 1.62-1.54 (4H, m, 2CH2), 1.44 (9H, s, 3CH3), 1.38-1.26 (4H, m, 2CH2).  
 
13C NMR (DMSO-d6, 126 MHz):  = 171.6, 171.2, 142.3, 126.1, 125.7, 124.1, 116.6, 
116.3, 96.1, 69.1, 64.1, 61.0, 39.7, 39.5, 36.4, 36.2, 29.0, 28.9, 25.7, 25.6.  
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N1-(2-Aminophenyl)-N6-ferrocenyladipamide, 110.  
Tert-butyl-2-(6-oxo-6-(phenylamino)hexanamido)ferrocenylcarbamate (520 mg, 1.00 
mmol, 1 equiv.) was suspended in dichloromethane (40 mL) and MeOH (4 mL). To this 
mixture 4N HCl/dioxane (8 mL) was added and the mixture was stirred at room 
temperature overnight. The volatiles were removed in vacuo, then sat. Na2CO3 (aq.) was 
added to the residue and the mixture was sonicated. The precipitate was collected by 
suction and washed on the frit with water, dried, triturated with CH2Cl2 to give the title 
compound as a brown solid (318 mg, 76%). 
1H NMR (DMSO-d6): 9.21 (1H, s, NH), 9.09 (1H, s, NH), 7.15 (1H, d, J=7.8 Hz, CH), 
6.78-6.73 (1H, m, CH), 6.70 (1H, dd, J=7.8, 1.4 Hz, CH), 6.53 (1H, dd, J=7.8, 1.4 Hz, 
CH), 4.80 (2H, s, NH2), 4.56 (2H, s, 2CH), 4.08 (5H, s, Cp), 3.92 (2H, s, 2CH), 2.36-2.32 
(2H, m, CH2), 2.25-2.10 (2H, m, CH2), 1.68-1.54 (4H, m, 2CH2).  
 
13C NMR (DMSO-d6, 126 MHz ):  = 171.4, 171.1, 142.3, 126.1, 125.7, 124.1, 116.6, 
116.3, 96.1, 69.2, 64.1, 61.1, 36.3, 36.1, 25.5.  
 
HRMS-ESI (m/z): found 420.1366, calc. for [C22H26FeN3O2]
+ 420.1369.  
 
Anal. calcd (%) for C22H25FeN3O2: C, 63.02; H, 6.01; N, 10.02.  
Found (%): C, 62.85; H, 6.05; N, 9.84. 
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N1-(2-Aminophenyl)-N8-ferrocenyloctanediamide, 111.  
Tert-butyl-2-(8-oxo-8-(phenylamino)octanamido)ferrocenyl carbamate (136.8 mg, 0.25 
mmol, 1 equiv.) was suspended in dichloromethane (10 mL) and MeOH (1 mL). To this 
mixture 4N HCl/dioxane (2 mL) was added and the mixture was stirred at room 
temperature overnight. The volatiles were removed in vacuo, then sat. Na2CO3 (aq.) was 
added to the residue and the mixture was sonicated. The precipitate was collected by 
suction and washed on the frit with water, dried, triturated with CH2Cl2 to give the title 
compound as a brown solid (82 mg, 73%). 
 
1H NMR (DMSO-d6): 9.18 (1H, s, NH), 9.05 (1H, s, NH), 7.14 (1H, dd, J=8.0, 1.5 Hz, 
CH), 6.91-6.84 (1H, m, CH), 6.70 (1H, dd, J=8.0, 1.5 Hz, CH), 6.54-6.48 (1H, m, CH), 
4.78 (2H, s, NH2), 4.57 (2H, t, J=1.9 Hz, 2CH), 4.08 (5H, s, Cp), 3.92 (2H, t, J=1.9 Hz, 
2CH), 2.31 (2H, t, J=7.4 Hz, CH2), 2.15 (2H, t, J=7.4 Hz, CH2), 1.68-1.53 (4H, m, 2CH2), 
1.35-1.29 (4H, m, 2CH2).  
 
13C NMR (DMSO-d6, 126 MHz):  = 171.6, 171.2, 142.3, 126.1, 125.7, 124.1, 116.6, 
116.3, 96.1, 69.1, 64.1, 61.0, 39.7, 39.5, 36.4, 36.2, 29.0, 28.9, 25.7, 25.6. 
 
HRMS-ESI (m/z): found 448.1675, calc. for [C24H30FeN3O2]
+ 448.1682.  
 
Anal. Calcd (%) for C24H29FeN3O2: C, 64.44; H, 6.53; N, 9.39.  
Found (%): C, 64.23; H, 6.60; N, 9.29. 
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Tert-butyl-2-(8-oxo-8-(phenylamino)octanamido)ferroceniumcarbamate 
tetrafluoroborate, 112.  
Tert-butyl-2-(8-oxo-8-(phenylamino)octanamido)ferrocenylcarbamate (109.5 mg, 0.2 
mmol, 1 equiv.) was suspended in dry DCM (5 mL). To this NOBF4 (37.4 mg, 0.32 mmol, 
1.6 equiv.) was added.34 The colour of the solution changed from yellow to dark brown. 
Filtration afforded the title compound as a dark brown solid (89 mg, 70%).  
 
19F NMR (DMSO-d6): -29.53.  
 
11B NMR (DMSO-d6): -2.56.  
 
C29H37BF4FeN3O4: C, 54.92; H, 5.88; N, 6.62.  
Found (%): C, 55.08; H, 5.84; N, 6.57. 
 
FTIR (cm-1): 992 (BF4
-). 
 
N1-(2-Aminophenyl)-N8-ferroceniumoctanediamide tetrafluoroborate, 113.  
N1-(2-Aminophenyl)-N8-ferrocenyloctanediamide (100 mg, 0.2 mmol, 1 equiv.) was 
suspended in dry DCM (5 mL). To this NOBF4 (37.4 mg, 0.32 mmol, 1.6 equiv.) was 
added. The colour of the solution changed from yellow to dark brown. Filtration afforded 
the title compound as a dark brown solid (78 mg, 73%).  
 
19F NMR (DMSO-d6): -29.53. 
 
11B NMR (DMSO-d6): -1.34.   
 
C24H29BF4FeN3O2: C, 67.12; H, 5.80; N, 9.49.  
Found (%): C, 66.97; H, 5.84; N, 9.31.  
 
FTIR (cm-1): 1038 (BF4). 
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HDAC isoform inhibition assay/profiling.  
(contributed by colleges from Harvard University) 
The inhibitory effect of compounds on the function of HDACs 1–9 was determined in 
vitro using an optimised homogenous assay performed in 384-well plate format as 
previously described.42  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HDAC IC50 (uM) HDAC IC50 (uM) HDAC IC50 (uM) HDAC IC50 (uM)
1 1.000 1 0.006 1 0.389 1 0.611
2 1.029 2 0.016 2 1.262 2 0.576
3 0.111 3 0.007 3 0.049 3 0.015
4 >30 4 26.230 4 >30 4 >30
5 >30 5 9.651 5 >30 5 >30
6 >30 6 0.004 6 >30 6 >30
7 >30 7 >30 7 >30 7 >30
8 >30 8 0.286 8 >30 8 >30
9 >30 9 >30 9 >30 9 >30
SAHAPojamide TC-H106 RGFP966
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Chapter 4 
Synthesis of ferrocene-based kinase inhibitors containing a 
pentafluorosulfanyl moiety. 
4.1 Overview 
 A series of SF5-oxindole analogues has been synthesized by a Knoevenagel 
condensation reaction and were tested for biological activity testing versus a panel of cell 
lines and protein kinases. The resulting compounds were characterized by elemental 
analyses, NMR spectroscopy, mass spectrometry, LC-MS and X-ray crystallography 
studies. 
 
4.2 Introduction 
Kinases are a group of enzymes responsible for phosphorylation of proteins, 
which are key steps in a number of biological processes. There are over 500 in humans. 
The phosphorylation step uses ATP to transfer the phosphate group (Scheme 4.1) usually 
to a serine, threonine or tyrosine residue, leading to a structural change in the protein and 
an intracellular signal. In disease, this step is uncontrolled and is responsible for a number 
of inflammatory disorders and cancers. Phosphorylation can modify the function of a 
protein in many ways. The structure of ATP is shown in Figure 4.1 and the 
phosphorylation diagram is shown in Scheme 4.1.1  
 
 
 
 
 
Figure 4.1. Adenosine triphosphate (ATP). 
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Scheme 4.1. Phosphorylation process with 3 examples of amino acids in the protein. 
 
 Many human cancers are related to the disregulation of protein kinases because 
of mutations. Protein kinases are an important target class for developing treatments. 
Phosphorylation is often a required step in the growth of some cancers and inflammatory 
disorders; hence the enzyme inhibitors that block the action of protein kinases will 
provide the treatment of diseases. Scheme 4.2 shows the receptor tyrosine kinase 
phosphorylation mechanism. In the first step an extracellular signalling molecule will 
attach to the signal binding site then each monomer will bind together and form a dimer, 
then the phosphate group from the ATP will attach to the tyrosine forming a 
“phosphorylated dimer”. In the next step, inactive protein will come to the molecule and 
attach to a phosphorylated tyrosine and this change will lead to the signal transduction 
pathway which leads to the cellular response.   
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Scheme 4.2. Receptor tyrosine kinase mechanism. 
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The epidermal growth factor receptor (EGFR) belongs to the ErbB family of 
receptor tyrosine kinases (RTK). ErbB is a gene of a protein family containing 4 receptor 
tyrosine kinases; ErbB-1 or EGFR, ErbB-2, ErbB-3 and ErbB-4. In the early 1990s, 
chloroanilinoquinazoline or CAQ (121) was studied and confirmed to be a potent 
inhibitor of EGFR tyrosine kinase by ICI Pharmaceuticals2-3 and a further structural  study 
showed that the anilinoquinazoline acts as a mimic of ATP. The replacement of the 
methoxy groups at positions 6 and 7 on the quinazoline ring provided an increase in 
potency, 4-(3-chloro-benzyl)-6,7-dimethoxy-quinazoline  (122).2  
 
      
 
 
 
 
 
 
Figure 4.2. CAQ, 121 and methoxy-CAQ, 122. 
 
  The discovery of 121 and 122 led to the drug gefitinib (or Iressa), which 
is an EGFR inhibitor used for non-small-cell lung cancer (NSCLC)4 but had limited 
effects on patients.5  
 
 
 
 
 
 
 
Figure 4.3. Gefitinib or Iressa. 
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 Erlotinib or Tarceva is also a drug used to treat non-small cell lung cancer 
(NSCLC), which acts on the epidermal growth factor receptor (EGFR).6 
 
 
 
 
 
 
Figure 4.4. Erlotinib or Tarceva. 
  
 There are a number of quinazoline-based inhibitors, which are now in active 
clinical development such as AZD0530 (123), AZD0424 (124), AZD3759 (125), 
AZD1522 (126) and AZD2811 (127).2 
 
 
 
Figure 4.5. Some quinazoline-based inhibitors. 
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 Kinase drugs for example, Imatinib (Gleevec, 128), Nilotinib (129), Bosutinib 
(130) and Ponatinib (131) have been approved for the treatment of chronic myelogenous 
leukemia (CML).7  
 
Figure 4.6. Some kinase drugs for CML. 
 
Whereas sunitinib (132), sorafenib (133), axitinib (134) and pazapanib (135) are used 
for treating various stages of renal cell cancer.7    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Some kinase drugs for renal cancer cell. 
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 Staurosporine8 is an alkaloid compound that exhibits activity against a wide range 
of protein kinases by the prevention of ATP binding with IC50’s in the nanomolar range 
but it is a non-specific protein kinase inhibitor and has high toxicity.9 Meggers’s group 
were interested in synthesizing Ru and Pt complexes (136, 137 and 138) where the sugar 
unit was replaced by square planar and octahedral complexes. These complexes made use 
of “hypervalent” carbon mimics (e.g. up to 6-valent Ru) compared to the staurosporine 
structure and their biological activity has been studied. These complexes are potent, 
selective inhibitors of protein kinases, attributed to the geometry enabled by the metal 
complexes compared with a tetrahedral carbon in the sugar unit.10-11  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Staurosporine, Ru and Pt complexes (136, 137 and 138). 
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Moreover, Meggers’s group has synthesized the Ir complex, 139 based on staurosporine’s 
structure and the result showed that 139 proved to be potent and selective towards the 
Flt4 kinase (protein encoded with gene Flt4 related to lymphangiogenesis and 
maintenance of the lymphatic endothelium).12 
 
 
   
 
 
 
 
 
Figure 4.9. Ir complex 139. 
 
    3-Substituted oxindole analogues, 140, 141 and 142 (oxindole or indolin-2-one is 
an aromatic heterocyclic compound) have been investigated for their inhibitory properties 
against various RTKs (receptor tyrosine kinases). The results showed 140 and 142 to be 
potent and selective inhibitors of the vascular endothelial growth factor (VEGF), Flk-1 
while 141 was shown to be unselective for RTK inhibition. In this study, it was shown 
that the 3-[(substituted pyrrolyl-, thienyl- and pyrazolyl)methylidenyl]indolin-2-ones (for 
example 143, 144 and 145 in Figure 4.11) exhibiting a Z configuration had high 
selectivity to VEGF (Flk-1) and/or PDGF (platelet-derived growth factor receptors) RTK 
activity, among them 143 showed the highest potency towards VEGF (Flk-1) and PDGF 
RTK.13  
 
 
 
 
 
 
 
    Figure 4.10. Oxindole and 3-substituted oxindole analogues 140, 141 and 142. 
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    Figure 4.11. Oxindole analogues of 143, 144 and 145. 
 
 The reaction between oxindole and ferrocene carboxaldehyde has been studied 
and the biological activities of the resulting compounds were tested against a number of 
kinases. The resulting products (E)- and (Z)-3-ferrocenylmethylidene-1,3-dihydro-2H-
indol-2-one 146 (E, major product and Z, minor product) displayed similar and significant 
activity  against VEGFR and PDGFR-RTKs.14  
 
 
 
 
 
 
 
 
 
        Figure 4.12. Oxindole analogues E and Z-146. 
 
 Later work showed the synthesis of similar derivatives and biological evaluation, 
versus kinases, of oxindole and ferrocene/ruthenocene analogues (compounds 146-156, 
including the previous E and Z-146 compounds) by using the Knoevenagel condensation 
reaction. The inhibition data showed some derivatives to have activity  against  different 
targets such as CLK1, DYRK3,VEGFR2 and DYRK4 but not on DYRK1 and DYRK2 
(DYRK is dual specificity tyrosine-phosphorylation-regulated kinase).15 
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    Figure 4.13. Oxindole analogues E and Z-146-151. 
 
 A number of small molecule kinase inhibitors have been approved by the FDA, 
also structural and binding information have been presented, which is extremely useful 
for studying new kinase inhibitors in the future. Figure 4.14 shows the structural binding 
mode of some small molecule kinase inhibitors (erlotinib, gefitinib and sunitinib).16      
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Figure 4.14. Structures and binding mode of some kinase inhibitors. 
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In this work, we aimed to synthesize kinase inhibitors based on an oxindole 
scaffold with a SF5 group to occupy the hydrophobic pocket.  
 
SF5, or pentafluorosulfanyl, is a stable group and it has led to multiple applications 
in material sciences and medicinal chemistry. A SF5 group is interesting as it has strong 
polarity, good physicochemical and biological activities, high density and high 
lipophilicity. SF5 and CF3 (trifluoromethyl) share many features for example; high 
electronegativity, lipophilicity, chemical and thermal stability, high stability under 
physiological conditions. The SF5 group has been shown to behave often like a CF3 
group.17-18 Although the two groups share similarities they are not always biologically 
equivalent.19-20  
 
Altomonte’s group have synthesized two series of –CF3 and –SF5 aniline-
pyrazoles compounds and their CB1 receptor affinities (Ki) were studied. In vitro assay 
results  showed the –SF5 compound (152, Ki = 11.2 nM) had the lower Ki value than the 
–CF3 ones (153, Ki = 26 nM).19 
 
 
  
  
 
 
 
 
 
Figure 4.15. –CF3 and –SF5 aniline-pyrazoles compounds 152 and 153. 
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 The pentafluorosulfanyl analogues of fluoxetine (154), fenfluramine (155) and 
nonfenfluramine (156) have been synthesized by replacing the CF3 group (157, 158 and 
159, respectively) with a SF5 group, then the potency against the 5-HT2b, 5-HT2c and 5-
HT6 receptors was studied (5-HT receptors or 5-hydroxytryptamine receptors are a group 
of G protein-coupled receptors). The literature results showed 159 had enhanced potency 
against 5-HT2b, 5-HT2c and 5-HT6 receptors.
20     
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16. SF5 group of fluoxetine 154, fenfluramine 155 and nonfenfluramine 156. 
 
 Other work from Wipf’s group published the synthesis of SF5 analogues of the 
antimalarial agent mefloquine, 160 and 161 then evaluated their biological activities 
against malaria parasites (mefloquine, 162 is medication used to prevent and treat 
malaria21 but there are many side effects of mefloquine such as anxiety, depression, 
hallucinations and seizures, etc.).22 The results showed 160 and 161 had improved 
activities compared to the parent CF3 - mefloquine compound.
23   
 
 
 
 
 
 
 
Figure 4.17. SF5 group of mefloquine 160, 161 and mefloquine 162. 
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4.3 Results and Discussion 
 We synthesized pyrrole and ferrocene compounds by using a Knoevenagel 
condensation reaction according to the published literature15 and explored SAR against a 
wide range of kinases. The previous oxindole compounds (Z)-146 and (E)-146 showed 
biological activity against PDGFR and VEGFR isoforms (Table 4.1)  
 
 
Scheme 4.3. Synthesis of SF5-oxindole analogues. 
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Table. 4.1. % Inhibition of (Z)-146 and (E)-146 vs VEGFR and PDGFR.                                      
– denotes inactive.14 
Compound % Inhibition 
hVEGFR-1 hVEGFR-2 hPDGFR-α hPDGFR-β 
(Z)-146 13 88 - 12 
(E)-146 15 91 - 10 
  
The structures of the pyrrole compounds 162 and 163 were confirmed by 1H 
NMR, 13C NMR spectroscopy, elemental analysis, mass spectrometry and X-ray 
crystallography. The yields of the products were between 65-74%. The 1H NMR spectra 
showed the most downfield signals were assigned to the 2 –NH groups ( 11.10-13.40 
ppm (the latter being an intramolecular NH-O=C hydrogen bond)). The results from 
elemental analysis and mass spectrometry corresponded to the calculated values and the 
solid state molecular structures of the two compounds were determined by X-ray 
crystallography and showed, as with 1H NMR, an intramolecular H- bond between the –
NH of the pyrrole ring and the C=O of the indole-2-one moiety.       
 
 
 
 
 
 
 
    
 
 
 
Figure 4.18. X-ray structure of 162. 
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Figure 4.19. X-ray structure of 163. 
 
The structures of ferrocenyl compounds 164 and 165 were confirmed by 1H NMR, 
13C NMR, elemental analysis, mass spectrometry and X-ray crystallography. The total 
yields were between 49-59%. The 1H NMR spectrum of the products showed the most 
downfield signal was assigned to –NH ( 10.84-10.94 ppm). The solid state molecular 
structures of two compounds were determined by X-ray crystallography and the isomers 
could be determined in solution by NOESY NMR, for example Figure 4.20 shows the 
NOESY NMR of (Z)-164 which is confirmed as the Z-isomer because as there is a proton 
at =6.92 ppm in proximity to another proton at =7.67 ppm.    
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Figure 4.20. NOESY NMR of (Z)-164 
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Figure 4.21. X-ray structure of (Z)-164. 
 
 
 
 
 
Figure 4.22. X-ray structure of (E)-164. 
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4.4 Biological Results 
4.4.1 Biochemical assays 
 We tested all the above 7 compounds against a number of kinases that were 
inhibited by related ferrocene-based oxindoles (Figures 4.12, 4.13) in a biochemical assay 
(CEREP, commercial screen) i.e. VEGFR, PDGFR and DYRK family kinases. Any 
compounds that showed appreciable (approx. 50%) inhibition at 1 M were tested over a 
dose range for IC50 values since these assays are relatively expensive. 
 
Table 4.2 shows the IC50 values against VEGFR3 (vascular endothelial growth factor 
receptor 3), PDGFRα (platelet-derived growth factor receptor), DYRK3 (dual specificity 
tyrosine-phosphorylation-regulated kinase 3), which were found to be hits from the initial 
screen. 
These compounds were also tested, in biochemical assays vs. novel kinases including 
AAK1 (adaptor-associated protein kinase1), BMP2K (bone morphogenic protein-2-
inducible kinase), GAK (cyclin G-associated kinase) and STK16 (serine/threonine-
protein kinase16) by the Structural Genomics Consortium (SGC, Oxford) and results are 
found in the same table. Fortunately, whether active or not, IC50 results were generated 
by our collaborators.  
 
 
 
 
 
 
 
 
 
 
128 
 
 
IC
5
0
 (
M
) 
STK16 
1
.7
6
 
1
0
-5
 
1
.3
5
 
1
0
-4
 
- - - - - 
1
.1
4

1
0
-7
 
GAK 
3
.4
2
 
1
0
-5
 
4
.7
6
 
1
0
-7
 
- - - - - 
1
.8
9
 
1
0
-8
 
BMP2K 
4
.5
2
 
1
0
-7
 
1
.8
7
 
1
0
-4
 
- - - - - 
3
.1
7
 
1
0
-9
 
AAK1 
1
.0
 
1
0
-6
 
1
.0
 
1
0
-3
 
- - - - - 
2
.4
7
 
1
0
-9
 
DYRK3 (h) 
- - 
1
.7
 
1
0
-6
 
2
.4
 
1
0
-6
 
- - - 
4
.5
 
1
0
-8
 
DYRK2 (h) 
- - - - - - - 
8
.3
 
1
0
-7
 
DYRK1a (h) 
- - - - - - - 
3
.2
 
1
0
-8
 
PDGFRβ 
kinase (h) 
- - - - - - - 
2
.5
 
1
0
-9
 
PDGFRα 
kinase (h) 
- 
9
.8
 
1
0
-8
 
- - - - 
3
.1
 
1
0
-9
 
1
.2
 
1
0
-9
 
KDR kinase (h) 
(VEGFR2) 
- - - - - - - 
2
.3
 
1
0
-9
 
FLT-4 kinase 
(h) (VEGFR3) 
- 
2
.3
 
1
0
-7
 
- - - 
5
.3
 
1
0
-7
 
1
.8
 
1
0
-8
 
7
.8
 
1
0
-1
0
 
FLT-1 kinase 
(h) (VEGFR1) - - - - - - - 
2
.8
 
1
0
-8
 
C
o
m
p
o
u
n
d
 
1
6
2
 
1
6
3
 
(Z
)-
1
6
4
 
(E
)-
1
6
4
 
(Z
)-
1
6
5
 
1
6
6
 
1
6
7
 
S
ta
u
r
o
sp
o
ri
n
e 
 
T
a
b
le
. 4
.2
. I
C
5
0
 v
al
u
es
 o
f 
7
 c
o
m
p
o
u
n
d
s 
v
s 
V
E
G
F
R
3
, P
D
G
F
R
α
, D
Y
R
K
, A
A
K
1
, B
M
P
2
K
, G
A
K
 
an
d
 S
T
K
1
6
. 
–
 d
en
o
te
s 
in
ac
ti
v
e.
 
129 
 
The position of the SF5 group is important for activity; (Z)-162 is inactive whereas (Z)-
163 shows sub micromolar activity vs. VEGFR3 (230 nM) and PDGFRα (98 nM, IC50). 
Both (E)- and (Z)-164 have low µM activity vs. DRYK3 whereas (Z)-165 is inactive. 
Again, the position of the SF5 group appears to be important; 166 has an IC50 of 530 nM 
whereas 167 has an IC50 of 18 nM vs. VEGFR3 and a very impressive 3.1 nM activity vs. 
PDGFRα. While both compounds of (Z)-162 and (E)-163 showed the activity vs. protein 
kinases; AAK1, BMP2K, GAK and STK16 but not on the remaining 5 compounds.  
 
 
 
 
 
 
 
 
 
 
Figure 4.23. Activity of a) 162, b) 163 and c) staurosporine in AAK1. 
 
 
 
 
 
 
a) b) 
c) 
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Figure 4.24. Activity of a) 162, b) 163 and c) staurosporine in BMP2K. 
 
 
 
 
 
 
 
 
 
Figure 4.25. Activity of a) 162, b) 163 and c) staurosporine in GAK. 
a) b) 
c) 
a) b) 
c) 
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Figure 4.26. Activity of a) 162, b) 163 and c) staurosporine in STK16. 
 
4.4.2 Cell-based assays 
Compounds 162-167 were next tested in breast cancer and normal healthy cells. 
The cell lines chosen were: MCF10A, which are breast cells, which are non-transformed, 
does not form tumours and are considered to be benign. These, as well as RPE cells 
(retinal pigment epithelium), would allow us to test the effects of our compounds on 
healthy cells, i.e. toxicity. MCF7, which are Luminal A, ER + and PR + (responsive to 
estrogen and progesterone, hence, estrogen and progesterone receptor positive) yet Her2 
negative (unresponsive to human epidermal growth factor receptor 2). Such cell lines 
could normally respond to e. g. tamoxifen, 16. T47D (Luminal A, ER +, PR +, Her2 -), 
MDA-MB-436 (abbreviated as MM36) and MDA-MB-231 (abbreviated as MM231) cell 
lines, both of which are triple negative (---) and cannot be treated with hormones or EGFR 
(HER2) inhibitors. These can be considered to be the most challenging to treat in the 
clinic. 
 
 
a) b) 
c) 
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Figure 4.27. Toxicity of compounds on MCF7 cells.  
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Figure 4.28. Toxicity of compounds on MM231 cells. 
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Figure 4.29. Toxicity of compounds on MM436 cells. 
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Figure 4.30. Toxicity of compounds on T47D cells. 
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Figure 4.31. Toxicity of compounds on non-cancerous MCF10A cells. 
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Figure 4.32. Toxicity of compounds on non-cancerous RPE cells. 
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Table 4.3 shows the GC50 values of compounds 162 and 163 in MCF7 and T47D. 
Compound GC50 (µM) 
MCF7 ±standard deviation T47D ±standard deviation 
162 3.75 2.70 0.49 0.40 
163 0.69 0.40 0.35 0.05 
 
Figure 4.33. Activity of 162 (red) and 163 (blue) in different cell lines. 
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Figure 4.33 displays MCF7 and T47D, which are very similar breast cancer cell 
lines and it is encouraging that the 162 and 163 have similar potency against both, with 
GC50s in the low micromolar range. While MDA-MB-231 and MDA-MB-436 are not 
affected (these are usually the most difficult to treat). The normal cell lines MCF10 are 
not affected. 
4.4.3 Modelling  
To explore the binding modes of 162 and 163 in PDGFRα (PDB: 5K5X) we performed 
docking studies and it showed both compounds bind to the ATP pocket. Docking was 
performed using molecular mechanics (AutoDock 4.2.6. using the Lamarckian Genetic 
Algorithm and empirical free energy scoring function). PDB format files for the ligand 
and kinase domain were pre-processed using AutoDock Tools 1.5.6.24 We found 163 
binds deeply in a predominantly hydrophobic pocket where 162 is shown in blue and 163 
is shown in green colour. The carbonyl group of 163 binds to the Asp backbone as shown 
in Figure 4.34. Also in Figure 4.35 are shown the zoom-in docking poses where the 
carbonyl group of 162 binds to the Cys backbone. The oxindole binds to the hinge region. 
163 fits nicely deep into the hydrophobic pocket. 163 has a higher potency compared to 
162 and Figure 4.36 shows the clash of 162 in PDGFRα. 
 
 
 
 
 
 
 
Figure 4.34. Docking poses of 162 (blue) and 163 (green) in PDGFRα. 
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Figure 4.35. Docking poses of 162 (blue) and 163 (green) in PDGFRα (zoom-in). 
Figure 4.36. Docking poses of SF5 group clashing in 162 (blue) in PDGFRα. 
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4.5 Conclusion 
 SF5-oxindole compound analogues have been synthesized, characterized by a 
number of spectroscopic techniques in solution and by X-ray crystallography in the solid 
state. They were tested for biological activity testing versus a panel of kinases and in 
cancer cell lines. Compounds 163 displayed good activity and by docking studies we 
showed that 163 nicely fits in the protein PDGFRα and more effectively than 162. 
Preliminary studies show these to have good activity in breast cancer cell lines. However, 
we need to further explore these inhibitors in order to gain an understanding of their 
mechanism of action. More kinase screens are needed to explore their selectivity and 
promiscuity as well as more cancer cell line work is needed. Are the cell line effects due 
to kinase inhibition, what are the expression levels of such kinases in cells, or are the cell 
effects due to the inhibition of other targets in the cell for example? 
  
4.6 Experimental 
5-(Pentafluorosulfanyl)-1,3-dihydro-indol-2-one and 6-(pentafluorosulfanyl)-
1,3-dihydro-indol-2-one were obtained from SpiroChem. Ferrocene carboxaldehyde, 
pyrrole-2-carboxaldehyde, piperidine and sodium chloride were obtained from Sigma-
Aldrich. Magnesium sulfate was obtained from Fisher Scientific. Preparative TLC was 
obtained from Analtech. Solvents and reagents were purchased from commercial 
suppliers and were used without purification. All reactions were performed in a fume 
hood. NMR spectra were recorded on Varian 500 MHz or 400 MHz spectrometers and 
chemical shifts are reported in ppm, usually referenced to TMS as an internal standard. 
LCMS were performed by Shimadzu LCMS-2020 equipped with a Gemini® 5µm C18 
110Å column and percentage purities were ran over 30 minutes in water/acetonitrile with 
0.1% formic acid (5 min at 5%, 5%-95% over 20 min, 5 min at 95%) with the UV detector 
at 254 nm. Mass spectrometry: ESI mass spectra were obtained using a Bruker Daltonics 
Apex III, using Apollo ESI as the ESI source. For EI mass spectra, a Fissions VG 
Autospec instrument was used at 70 eV. All analyses were run by Dr. Alla .K. Adbul-
Sada. Analyses are for the molecular ion peak [M]+ and are given in m/z, mass to charge 
ratio. Elemental analyses were conducted by Stephen Boyer (London Metropolitan 
University). The reactions for synthesis and purity of product were monitored by thin 
layer chromatography using TLC plates. 
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(Z)-3-((1H-pyrrol-2-yl)methylene-5-pentafluorosulfanylindoline-2-one, 162. 
 
The title compound was prepared by a Knoevenagel condensation reaction. 5-
(Pentafluorosulfanyl)1,3-dihydro-indol-2-one (129.6 mg, 0.5 mmol), pyrrole-2-
carboxaldehyde (57.06 mg, 0.6 mmol), ethanol (5 mL) and piperidine 3 drops were 
subjected to the microwave irradiation by ramping to 150C and were held at that 
temperature for 30 minutes. TLC analysis of the cooled reaction mixture monitored 
consumption of starting materials. The crude reaction mixture was extracted with ethyl 
acetate (2×10 cm3) and washed with deionised water (10 mL) and brine (2×10 mL), the 
organic layer was dried using magnesium sulphate then filtered through a cotton wool 
plug. The crude mixture was concentrated in vacuo and purified using silica gel column 
chromatography using 3:7 hexane/diethyl ether to give an orange solid. The yield was 
105 mg, 65%. Crystallization by mixed solvents, CH2Cl2 and hexane, provided orange 
crystals. 
 
1H NMR (DMSO-d6, 500MHz):  = 13.22 (1H, s, NH), 11.30 (1H, s, NH), 8.24 (1H, d, J 
= 2.3 Hz, CH), 8.11 (1H, s, CH), 7.65 (1H, dd, J = 8.6, 2.2 Hz, CH), 7.44 (1H, d, J = 2.2 
Hz, CH), 7.02 (1H, d, J = 8.6 Hz, CH), 6.92 (1H, d, J = 3.6 Hz, CH), 6.41 (1H, dd, J = 
3.6, 2.2 Hz, CH).  
 
13C NMR (DMSO-d6, 126 MHz):  = 169.9, 147.5, 141.5, 130.0, 129.5, 127.6, 125.9, 
124.7, 122.5, 116.7, 115.2, 112.3, 109.6. 
 
HRMS-ESI (m/z) found: 337.0431, calc. for [C13H9F5N2OS + H]
+ 337.0429. 
 
Anal. Calcd (%) for C13H9F5N2OS: C, 46.43; H, 2.70; N, 8.33.  
Found (%): C, 46.55; H, 2.61; N, 8.21. 
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(Z)-3-((1H-pyrrol-2-yl)methylene-6-pentafluorosulfanylindoline-2-one, 163. 
The title compound was prepared by a Knoevenagel condensation reaction. 6-
(Pentafluorosulfanyl)1,3-dihydro-indol-2-one (129.6 mg, 0.5 mmol), pyrrole-2-
carboxaldehyde (57.06 mg, 0.6 mmol), ethanol (5 mL) and piperidine 3 drops were 
subjected to the microwave irradiation by ramping to 150C and were held at that 
temperature for 30 minutes. TLC analysis of the cooled reaction mixture monitored 
consumption of starting materials. The crude reaction mixture was extracted with ethyl 
acetate (2×10 mL) and washed with deionised water (10 mL) and brine (2×10 mL), the 
organic layer was dried using magnesium sulphate then filtered through a cotton wool 
plug. The crude mixture was concentrated in vacuo and purified using silica gel column 
chromatography using 3:7 hexane/ethyl acetate and trituration with hexane to give brown-
orange solid. The yield was 142 mg, 74%. Crystallization by DCM provided orange 
crystals. 
 
1H NMR (DMSO-d6, 500MHz):  = 13.31 (1H, s, NH), 11.14 (1H, s, NH), 7.99 (1H, s, 
CH), 7.81 (1H, d, J = 8.6 Hz, CH), 7.53 (1H, dd, J = 8.6, 2.0 Hz, CH), 7.48 (1H, s, CH), 
7.26 (1H, d, J = 2.0 Hz, CH), 6.93 (1H, m, CH), 6.43 (1H, dd, J = 3.7, 2.1 Hz, CH). 
 
13C NMR (DMSO-d6, 126 MHz):  = 169.5, 138.8, 130.2, 130.0, 129.6, 128.3, 123.1, 
119.1, 118.7, 114.7, 112.7, 107.0.  
 
HRMS-ESI (m/z) found: 337.0432, calc. for [C13H9F5N2OS + H]
+  337.0429.  
 
Anal. Calcd (%) for C13H9F5N2OS: C, 46.43; H, 2.70; N, 8.33.  
Found (%): C, 46.59; H, 2.61; N, 8.17. 
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5-Pentafluorosulfanyl-3-ferrocenylindolin-2-one, 164. 
5-Pentafluorosulfanyl-3-ferrocenylindolin-2-one was prepared by a Knoevenagel 
condensation reaction. 5-(Pentafluorosulfanyl)1,3-dihydro-indol-2-one (259.2 mg, 1.0 
mmol), ferrocenecarboxaldehyde (256.8 mg, 1.2 mmol), ethanol (10 mL) and piperidine 
6 drops were subjected to the microwave irradiation by ramping to 150C and were held 
at that temperature for 30 minutes. TLC analysis of the cooled reaction mixture monitored 
consumption of starting materials. The crude reaction mixture was extracted with ethyl 
acetate (2×10 mL) and washed with deionised water (10 mL) and brine (2×10 mL), the 
organic layer was dried using magnesium sulphate then filtered through a cotton wool 
plug. The crude mixture was concentrated in vacuo and purified using preparative TLC 
using 3:7 hexane/ethyl acetate to give fraction 1 ( purple solid 160 mg, 35%) and fraction 
2 (red solid 109 mg, 24%). Crystallization of fraction 1 was by mixed solvents CH2Cl2 
and hexane and fraction 2 was by CH2Cl2. 
 
(Z)-164: (Z)-5-pentafluorosulfanyl-3-ferrocenylindolin-2-one.   
 
1H NMR (DMSO-d6, 500MHz):  = 10.84 (1H, s, NH), 8.23 (1H, s, CH), 7.98 (1H, s, 
CH), 7.68 (1H, d, J=8.6, CH), 6.92 (1H, d, J = 8.6 Hz, CH), 5.37 (2H, s, 2CH), 4.69 (2H, 
s, 2CH), 4.22 (5H, s, Cp) 
 
13C NMR (CDCl3-d, 126 MHz):  = 167.7, 141.9, 125.1, 119.3, 116.0, 110.0, 108.4, 74.0, 
73.3, 70.0, 60.3, 14.2.  
 
HRMS-ESI (m/z) found: 455.0065, calc. for [C19H14F5FeNOS]
+ 455.0060.   
 
Anal. Calcd (%) for C19H14F5FeNOS: C, 50.13; H, 3.10; N, 3.08.  
Found (%): C, 50.22; H, 3.03; N, 3.07. 
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(E)-164: (E)-5-Pentafluorosulfanyl-3-ferrocenylindolin-2-one.   
 
1H NMR (DMSO-d6, 500MHz):  = 10.94 (1H, s, NH), 8.30 (1H, s, CH), 7.76(1H, d, 
J=8.4, CH), 7.65-7.71 (1H, m, CH), 7.01 (1H, d, J=8.4, CH), 4.79-7.81 (4H, m, 4CH), 
4.29 (5H, m, Cp). 
 
13C NMR (CDCl3-d, 126 MHz):  = 171.1, 141.8, 109.0, 88.2, 72.6, 71.7, 70.2, 60.3, 31.5, 
29.6, 22.6, 20.9, 19.0, 14.1, 14.0.  
 
HRMS-ESI (m/z) found: 455.0064, calc. for [C19H14F5FeNOS]
+ 455.0060.   
 
Anal. Calcd (%) for C19H14F5FeNOS: C, 50.13; H, 3.10; N, 3.08.  
Found (%): C, 50.27; H, 3.23; N, 3.10. 
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(Z)-6-Pentafluorosulfanyl-3-ferrocenylindolin-2-one, 165. 
The title compound was prepared by a Knoevenagel condensation reaction. 6-
(Pentafluorosulfanyl)1,3-dihydro-indol-2-one (129.6 mg, 0.5 mmol), 
ferrocenecarboxaldehyde (128.4 mg, 0.6 mmol), ethanol (5 mL) and piperidine 3 drops 
were subjected to the microwave irradiation by ramping to 150C and were held at that 
temperature for 30 minutes. TLC analysis of the cooled reaction mixture monitored 
consumption of starting materials. The crude reaction mixture was extracted with ethyl 
acetate (2×10 mL) and washed with deionised water (10 mL) and brine (2×10 mL), the 
organic layer was dried using magnesium sulphate then filtered through a cotton wool 
plug. The crude mixture was concentrated in vacuo and purified using preparative TLC 
using 3:7 hexane/diethyl ether to give a purple solid. The yield was 111.53 mg, 49%. 
 
1H NMR (CDCl3-d, 500MHz):  = 8.02 (1H, d, J = 8.6 Hz, CH), 7.84 (1H, s, NH), 7.72 
(1H, s, CH), 7.54 (1H, m, CH), 7.40 (1H, dd, J = 8.6, 2.2 Hz, CH), 4.80 (2H, m, 2CH), 
4.70 (2H, m, 2CH), 4.28 (5H, s, Cp). 
 
13C NMR (CDCl3-d, 126 MHz):  = 199.5, 163.1, 136.1, 130.8, 128.8, 121.9, 72.5, 71.8, 
70.2, 29.3.  
 
HRMS-ESI (m/z) found: 455.0064, calc. for [C19H14F5FeNOS]
+ 455.0060.   
  
Anal. Calcd (%) for C19H14F5FeNOS: C, 50.13; H, 3.10; N, 3.08.  
Found (%): C, 50.21; H, 2.99; N, 3.12. 
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(Z)-3-(2,4-Dimethyl-5-((5-pentafluorosulfanyl-2-oxoindolin-3-ylidene)methyl)-1H-
pyrrol-3-yl)propanoic acid, 166. 
The title compound was prepared by a Knoevenagel condensation reaction. 5-
(Pentafluorosulfanyl)1,3-dihydro-indol-2-one (106 mg, 0.41 mmol), 3-(5-formyl-1H-
pyrrole-3-yl)propanoic acid (97.6 mg, 0.5 mmol), ethanol (6 mL) and piperidine 5 drops 
were subjected to the microwave irradiation by ramping to 150C and were held at that 
temperature for 30 minutes. TLC analysis of the cooled reaction mixture monitored 
consumption of starting materials. The crude reaction mixture was dried, washed with 
hexane and CH2Cl2 to give a brown solid. The yield was 141 mg, 79%. 
 
1H NMR (DMSO-d6, 500MHz):  = 13.46 (1H, s, OH), 8.40 (1H, s, NH), 7.86 (1H, s, 
NH ), 7.55 (1H, d, J = 8.6 Hz, CH), 6.98 (1H, J = 8.6 Hz, CH), 2.77-2.72 (2H, m, 2CH), 
2.62 (2H, t, J = 7.7 Hz, CH2), 2.31 (3H, s, CH3), 2.28-2.22 (2H, s, CH2), 1.48 (3H, s). 
 
13C NMR (DMSO-d6, 126 MHz):  = 186.1, 174.6, 170.0, 140.1, 136.8, 132.7, 126.7, 
126.3, 123.6, 116.2, 110.4, 109.0, 88.3, 88.2, 35.2, 20.0, 12.5, 10.1.  
 
HRMS-ESI (m/z) found: 459.0772, calc. for [C18H17F5N2NaO3S]
+ 459.0772.   
  
Anal. Calcd (%) for C18H17F5N2O3S: C, 49.54; H, 3.93; N, 6.42.  
Found (%): C, 49.63; H, 4.04; N, 6.48. 
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(Z)-3-(2,4-Dimethyl-5-((6-pentafluorosulfanyl-2-oxoindolin-3-ylidene)methyl)-1H-
pyrrol-3-yl)propanoic acid, 167. 
The title compound was prepared by a Knoevenagel condensation reaction. 6-
(Pentafluorosulfanyl)1,3-dihydro-indol-2-one (106 mg, 0.41 mmol), 3-(5-formyl-1H-
pyrrole-3-yl)propanoic acid (97.6 mg, 0.5 mmol), ethanol (6 mL) and piperidine 5 drops 
were subjected to the microwave irradiation by ramping to 150C and were held at that 
temperature for 30 minutes. TLC analysis of the cooled reaction mixture monitored 
consumption of starting materials. The crude reaction mixture was dried, washed with 
hexane and CH2Cl2 to give a brown solid. The yield was 136 mg, 76%. 
 
1H NMR (DMSO-d6, 500MHz):  = 13.50 (1H, s, OH), 10.87 (1H, s, NH), 7.90 (1H, d, J 
= 8.6 Hz, CH), 7.74 (1H, s, NH), 7.46 (1H, dd, J = 8.6, 2.1 Hz, CH), 7.24 (1H, d, J = 2.1 
Hz, CH), 2.78-7.69 (1H, m, CH), 2.66-2.61 (2H, m, CH2), 2.34-2.27 (6H, m, 2CH3), 2.25 
(1H, s, CH), 1.5 (1H, s, CH). 
 
13C NMR (DMSO-d6, 126 MHz):  = 174.5, 169.7, 137.8, 133.2, 130.4, 126.9, 123.9, 
117.9, 109.8, 88.3, 88.2, 44.4, 35.1, 23.1, 22.5, 20.0, 12.5, 9.96.  
 
HRMS-ESI (m/z) found: 459.0776, calc. for [C18H17F5N2NaO3S]
+ 459.0772.   
  
Anal. Calcd (%) for C18H17F5N2O3S: C, 49.54; H, 3.93; N, 6.42.  
Found (%): C, 49.70; H, 4.09; N, 6.56. 
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Chapter 5 
Conclusion, future directions and thesis outcomes. 
 
5.1 Conclusion 
 Ferrocene in medicinal chemistry has attracted attention as a benefit of its 
properties (mentioned in Chapter 1). Ferrocene complexes have been increasingly made 
and their activities have been studied. In this thesis, we aimed to synthesize the novel 
compounds by using the ferrocene molecule as a bioisostere and testing for different 
applications/targets (Scheme 5.1).      
 
 
 
 
 
 
 
 
Scheme 5.1. Project objectives. 
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 In Chapter 1 a review of ferrocenes and similar metal-based drugs is presented.  
 In Chapter 2, 10 novel compounds have been made by replacement of a 1-adamantyl 
group with ferrocene. Biological in vitro binding assay data show the new ferrocene compounds 
display good CB2 affinity (cannabinoid receptor). Also, the CB2 affinity of ferrocene derivatives 
is still maintained when compared with the 1-adamantyl compounds (Figure 5.1). The results 
showed many of our compounds displayed nM potency vs. the CB1 and CB2 receptors and that 
the intramolecular hydrogen bond is very important for their affinity. 
  
 
 
 
 
 
 
    
 
 
 
 
 
Figure 5.1. The replacement of a 1-adamantyl group by ferrocene. 
 
 In Chapter 3, benzamide compounds were made and biological data showed N1-
(2-aminophenyl)-N8-ferrocenyloctanediamide, (Pojamide) 111 to display nanomolar 
potency vs. HDAC3 compared to RGFP966. Pojamide and SNP (sodium nitroprusside) 
combinations led to greatly enhanced cytotoxicity and DNA damage attributed to 
activation to an Fe(III)-Poj species. 
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Figure 5.2. Pojamide, 111 and Fe(III)-Poj, 113. 
 
 In Chapter 4, a series of oxindole compound have been synthesized, by the 
Knoevenagel condensation reaction, for biological activity testing versus a panel of cell 
lines and protein kinases. Further studies are in progress to look at their effects on kinases 
in biochemical and cell assays. 
 
 
 
 
 
 
 
Figure 5.3. A series of oxindole compounds. 
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5.2 Future directions 
 FAAH (fatty acid amide hydrolase) inhibitors based on an aminoferrocene 
backbone compounds have been synthesized by using ferrocene as a bioisostere of 1-
adamantyl group and we are awaiting biological data.  
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Compound structures of 84, 85 and 86. 
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